

Transforaminal Versus Interlaminar Endoscopic Lumbar Discectomy for Lumbar Disc Herniation: A Systematic Review and Meta-Analysis

Global Spine Journal 2023, Vol. 13(2) 575–587 © The Author(s) 2022 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/21925682221120530 journals.sagepub.com/home/gsj

Khanathip Jitpakdee, MD¹, Yanting Liu, MD², Vit Kotheeranurak, MD^{3,4}, and Jin-Sung Kim, MD, PhD²

Abstract

Study Design: Meta-analysis and systematic review.

Objective: This study aims to investigate and compare patient-reported outcomes, perioperative data, and complications between 2 common endoscopic approaches for lumbar disc herniation: transforaminal and interlaminar endoscopic lumbar discectomy, by published high-quality evidence.

Methods: Electronic databases were searched for reported outcomes following TELD and IELD. Oswestry Disability Index (ODI), visual analog scale of back (VASB) and leg pain (VASL), and MacNab criteria were evaluated. Operative time, hospital stays, blood loss, radiation exposure, and complications were investigated. Odds ratio (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using random and fixed-effect models.

Results: Total of 1948 patients from 18 studies were included, consisting of 1006 patients (51.6%) in TELD group and 942 (48.4%) patients in IELD group. TELD had better improvement of postoperative ODI (MD = 1.26; 95% CI: .07-2.16; P = .04), postoperative VASB (MD = -.23; 95% CI: -.40 to -.05; P = .01) and last follow-up VASB (MD = -.25; 95% CI: -.41 to -.09; P = .002), but with longer operative time (MD = 10.1 min; 95% CI: 1.925-18.77; P < .00001) and more fluoroscopic time (SMD = 4.12; 95% CI: 3.22-5.03; P < .00001), especially in L5-S1 operation. Bed rest time was significantly longer following IELD, with no difference in VASL, hospital stays, or complication.

Conclusion: We found comparable clinical outcomes in terms of ODI, VAS, patient satisfaction, hospital stays, and complication between both techniques. TELD required more radiation exposure and longer operative time at L5-S1 level than IELD. Our study provided results to help consider appropriate approaches for selected patients and informed consent of benefits from each approach.

Keywords

disc herniation, endoscopic, interlaminar, transforaminal, discectomy, IELD, TELD, PELD

³ Department of Orthopaedics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Corresponding Authors:

Jin-Sung Kim, MD, PhD, Department of Neurosurgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seocho gu, Seoul 06591, South Korea.

Emails: mdlukekim@gmail.com; mdldavid@catholic.ac.kr



Creative Commons Non Commercial No Derivs CC BY-NC-ND: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

¹ Department of Orthopedics, Thai Red Cross Society, Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand

² Department of Neurosurgery, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea

⁴ Center of Excellence in Biomechanics and Innovative Spine Surgery, Chulalongkorn University, Bangkok, Thailand

Introduction

Lumbar disc herniation (LDH) is one of the most common spinal disorders predominantly affecting lower lumbar nerve roots. Symptoms occurred when the herniated intervertebral disc causes mechanical compression and inflammation of the adjacent nerve root, leading to radicular pain, numbness, or weakness of the lower limb.¹ Despite various non-surgical interventions available, many patients with LDH failed conservative treatment and ultimately required surgery to remove the herniated disc material and decompress the affected nerve root.² Microdiscectomy is the standard surgical procedure for treating LDH.¹ Due to an attempt to reduce surgical invasiveness, a spinal endoscope has been developed and applied to perform discectomy with many published evidence of its effectiveness and safety.^{3,4} As a minimally invasive surgery procedure, endoscopic lumbar discectomy requires a small incision with significantly reduced damage to the spinal musculature while providing excellent visualization of the spinal anatomy through different approaches.^{5,6} The endoscopic lumbar discectomy can be divided into 2 main approaches, the transforaminal lumbar endoscopic discectomy (TELD) described by Kambin⁷ and interlaminar lumbar endoscopic discectomy (IELD) described by Choi and Ruetten.⁸⁻¹⁰ Both techniques have been proved to successfully provide good surgical outcomes with low complications in treating LDH. However, consensus on the standard for decision making to use which approach has not been reached, and results of comparative studies between these techniques have been inconsistent. To the best of our knowledge, a systematic review and meta-analysis regarding approaches of endoscopic lumbar discectomy had rarely been investigated. Therefore, the goals of this study were to collect and comprehensively analyze the reliable evidence on comparison of outcomes following TELD and IELD for treating LDH including functional outcomes, perioperative data, and complications (Figure 1).

Material and Methods

Literature Searches

We conducted a systematic review and meta-analysis in line with the Preferred Reporting Items for Systematic Review and Metaanalysis (PRISMA) guidelines. Since the endoscopic lumbar discectomy was first reported in 1973, all articles published from January 1973 until 31 March 2022, were electronically retrieved. MEDLINE, Embase, and Scopus were searched for peerreviewed published articles including retrospective and prospective studies of outcomes following endoscopic discectomy for LDH that compare transforaminal and interlaminar approaches. We used the following search terms: endoscopic, discectomy, disc herniation, PELD, transforaminal, TELD, interlaminar, and IELD. All reference lists in the retrieved studies were manually checked for relevance and suitability.



Figure 1. PRISMA (Preferred Reporting Items for Systematic Review and Meta-analysis) flow diagram.

Inclusion and Exclusion Criteria

The inclusion criteria for our meta-analysis were: (1) published retrospective or prospective studies, (2) including more than 10 patients in each group with at least 3 months of follow-up period, (3) focusing on comparing TELD and IELD for treatment of LDH, (4) providing sufficient data including operative data, postoperative clinical or functional outcomes or complications and (5) articles written in the English language. Studies were excluded if they met any of the following criteria: (1) case series, case reports, or technical notes, (2) review articles, (3) duplicated reports, or (4) incomplete statistical data. The titles and abstracts of all reports were manually screened then full-text studies were assessed for eligibility according to the inclusion and exclusion criteria. The included reports were thoroughly reviewed and relevant data were recorded. The screening process of all eligible studies was organized by Covidence Systematic Review Software (Veritas Health Innovation, Melbourne, VIC, Australia).

Outcomes

Baseline characteristics of patients in each record were obtained, including author name, country, study type, number of subjects, age, sex, disc location, and follow-up time. The primary outcome was patient-reported outcome measure in a form of Oswestry Disability Index (ODI), visual analog scale of back (VASB) and leg pain (VASL) improvement, and MacNab evaluation (excellent/good/fair/poor). Secondary outcomes included perioperative data and complications. Perioperative data concerning operative time, fluoroscopic time, estimated blood loss, length of hospital stays, and postoperative bed rest time were recorded. Complications were obtained with subgroup analysis on dural tear and recurrent disc herniation.

Data Extraction and Quality Assessment

Data were extracted and assessed the quality by 2 authors (KJ and YL) independently using the Review Manager 5.4 (Cochrane Collaboration). Any disagreement between the 2 authors was solved by a discussion with the third author to reach a consensus. The quality of the eligible studies and risk of bias were evaluated using the Newcastle-Ottawa scale (NOS), which consists of 3 major categories: selection, comparability, and exposure, with a maximum of 9 stars to be assigned to each included study.

Statistical Analysis

Data analyses were processed with Review Manager 5.4 (Cochrane Collaboration). Odds ratio (OR) were used for comparison of dichotomous variables, including MacNab evaluation and complications. Mean difference (MD) and

standard mean difference (SMD) with 95% confidence interval (CI) were used for continuous data, including age, operative time, fluoroscopy time, hospital stay, bed rest time, ODI, and VAS score. The heterogeneity among included studies was assessed by the degree of inconsistency (I² statistic). The fixed-effect model was used for data without significant heterogeneity (P > .05, I² < 50%), and the random-effect model was applied if the data had significant heterogeneity. The risk of bias assessment among the studies was investigated with the funnel plot. A P-value < .05 was defined as statistically significant.

Results

Study Characteristics and Quality Assessment

The characteristics and information of the included studies were listed in Table 1. A total of 18 studies was included in this meta-analysis, consisting of 2 randomized controlled trials (RCT), 2 non-randomized prospective studies (PCS), and 14 retrospective studies (RCS). Most of the studies (11/18) were conducted in China. A total of 1948 participants were included, comprising 1006 (51.6%) and 942 (48.4%) patients in the TELD and IELD groups, respectively. The mean age of the participants in both groups varied from 34.6 to 56.7 years. In the TELD group, 530 male and 363 female participants were included, in the IELD group, there were 454 male and 379 female participants. All studies reported the average follow-up time which varied from 3 months to 27.6 months. Operative time, fluoroscopy times, estimated blood loss, hospital stays, postoperative bed rest time, improvement of postoperative and last follow-up VAS, improvement of postoperative and last follow-up ODI, MacNab evaluation, and complications were the analysis endpoints.

Overall, the quality of the included studies was relatively high based on the NOS. The quality assessments according to NOS were summarized in Table 2 for nonrandomized studies. The risk of bias assessment according to The Cochrane Collaboration Tool for randomized controlled trials were depicted in Table 3.

Demographics

Demographic characteristics of the TELD and IELD groups were summarized in Table 1. For comparisons of sex, age, and follow-up time, no obvious heterogeneity was observed. Demographic data were not significantly different between TELD and IELD group, regarding sex (male vs female; OR = 1.18; 95% CI: .95-1.45; P = .14), age (MD = -.41 years; 95% CI: -1.49-.68; P = .46), and follow-up time (MD = -.41 months; 95% CI: -1.32-.50; P = .37).

Similarly, no significant heterogeneity of preoperative functional scores (ODI, VASB, and VASL) was detected

| | | Study | | | | No. of | | | | Preop- | Preop- | Follow-up |
|---------|-----------------------------|-------------|----------|----------------------------------|-----------|-----------------------|---------------------------|-----------------|-----------------------|-----------------|--------------------|--------------|
| Ŷ | Author, year | design | Country | Level | Operation | patients (%) | Age (year) | Sex (M/F) | Preop-ODI | VASL | VASB | (mo) |
| _ | Bamrungthin ¹¹ | RCS | Thailand | L4-5 | TELD | 33 (38.8) | 45.I ± 9.7 | 20/13 | ٩N | AA | ٩N | 24 |
| |) | | | | IELD | 52 (61.2) | 43.8 ± 11.8 | 24/28 | ΝA | ٩N | ٩N | 24 |
| 7 | Chen et al. ²⁶ | RCS | China | L4-5, L5-SI | TELD | 27 (67.5) | 45.5 ± 7.5 | 19/8 | 57.6 ± 17 | 5.9 ± 1.7 | ٩N | 24.2 ± 3.9 |
| | : | | | | IELD | 13 (32.5) | 46.9 ± 6.9 | 8/5 | 58.2 ± 15.2 | 5.8 ± 1.5 | ٩Z | 23.0 ± 3.4 |
| m | Cheng et al. ¹² | RCS | China | L5-SI | TELD | 26 (48.2) | 37.73 ± 8.33 | 15/11 | 71.31 ± 10.2 | 7.54 ± .91 | A Z | 15.73 ± 3.71 |
| | 30 | | | | IELD | 28 (51.8) | 37.46 ± 6.68 | 15/13 | 70.79 ± 9.15 | 7.64 ± .91 | ٩Z | 15.93 ± 3.03 |
| 4 | Choi et al. ⁴³ | RCS | Korea | L5-SI | TELD | 30 (50) | 33.8 ± 10.1 | 14/16 | 52.3 ± 15.8 | 7.4 ± 1.5 | 5.2 ± 2 5.1 ÷ 5 | 26.4 ± 3.6 |
| Ľ | Choi of al 13 | | K orea | 4 5 1 5 6 1 6 1 1 | | 30 (50) 157 (54 3) | 36. ± 1.6 45.5 + 4. | 61/61 87/001 | 01.4 ± 18.1 NA | 7.6 ± 1.4 N∆ | 0.1 ± 0.0 ∆IA | 2/.6 ± 4.8 |
| n | | 2 | NOICA | LI-2, L2-3, L3-7, L4-5, L5-SI | IELD | 132 (45.7) | 49 ± 13.7 | 78/54 | K K Z Z | ₹₹ | Z Z | 2 2 |
| 9 | Gao et al. ¹⁴ | RCS | China | L5-SI | TELD | 38 (50) | 41.12 ± 10.12 | 21/17 | 67.85 ± 16.57 | 7.22 ± .96 | ٩N | 12 |
| | | | | | IELD | 38 (50) | 39.53 ± 9.91 | 18/20 | 68.02 ± 15.77 | 7.19 ± .98 | ٩Z | 12 |
| 2 | Huang et al. ¹⁵ | RCS | China | L4-5 | TELD | 37 (48.1) | 43.7 ± 12.7 | 26/11 | 73.5 ± 6.4 | 6.6 ± l | 3.8 ± 1.7 | 20.5 ± 5.0 |
| | | | | | IELD | 40 (51.9) | 45.7 ± 12.5 | 27/13 | 76.I ± 6.2 | 6.9 ± I.I | 3.4 ± 1.7 | 22.6 ± 5.9 |
| œ | Jiang et al. ¹⁶ | RCS | China | L2-3, L3-4, L4-5, | TELD | 65 (45.5) | AN | ΝA | 51.7 ± 15.4 | ٩N | 4.7 ± 1.5 | 9 |
| | | | | L5-SI | IELD | 78 (54.5) | AN | ٩Z | 52.1 ± 17.4 | ΔA | 3.9 ± 2.1 | 6 |
| 6 | Liu et al. ¹⁷ | RCS | China | L3-4, L4-5, L5-SI | TELD | 31 (53.4) | 38.5 ± 7.8 | 18/13 | ٩N | ٩N | ٩Z | m |
| | | | | | IELD | 27 (46.6) | 38.5 ± 6.2 | 15/12 | AN | AN | ٩Z | m |
| 0 | Mlaka et al. ²⁷ | PCS | Slovakia | L3-4, L4-5, L5-SI | TELD | 103 (55.4) | 47 | 51/52 | 39.09 ± 14.01 | 7.34 ± 2.07 | 5.35 ± 2.97 | 12 |
| | : | | | | IELD | 83 (44.6) | 43 | 44/39 | 43.36 ± 15.98 | 7.19 ± 2.01 | 4.31 ± 3.27 | 12 |
| = | Mo et al. ^{I8} | RCT | China | L5-SI | TELD | 39 (48.8) | 40.87 ± 11.99 | 24/15 | 74.42 ± 10.3 | 6.9 ± 1.17 | ٩N | 16.59 ± 4.10 |
| | | | | | IELD | 41 (51.2) | 43.34 ± 13.27 | 18/23 | 76.34 ± 8.8 | 7.05 ± 1.07 | ٩Z | 16.71 ± 3.72 |
| 12 | Nie et al. ¹⁹ | RCT | China | L5-SI | TELD | 30 (50) | 36.6 | 18/12 | 60.I ± 13.7 | 7.6 ± 1.4 | ٩Z | 27.7 |
| | | | | | IELD | 30 (50) | 38.2 | 20/10 | 59 ± 16 | 7.9 ± 1.42 | ٩Z | |
| <u></u> | Rajamani | RCS | India | L2-3, L3-4, L4-5, | TELD | 86 (50) | 39.4 ± 12.38 | 55/31 | 74.92 ± 10.83 | 8.68 ± 2.71 | 3.98 ± .81 | 24 |
| | et al. | | ; | L5-SI | | 86 (50) | 39.4 ± 10.23 | 54/32 | <i>1</i> 3.23 ± 12.34 | 8.69 ± 1.52 | 3.81 ± .52 | 24 |
| 4 | Sebben et al. ²⁰ | S | Brazil | L3-4, L4-5, L5-SI | | 24(43.7) | A Z | A Z | A Z | A Z | ۲ A | 2 2 |
| 5 | Wei ef al ²¹ | S C S | China | וצ־טו | | 31(20.3) 87 (45 3) | NA 459 + 106 | 43/44 | 45 9 + 9 | 7 + 1 7 | | 2 2 |
| 2 | | | | | IELD | 105 (54.7) | 43.5 ± 11.8 | 47/58 | 46.1 ± 7.3 | 6.9 ± 1.3 | X A Z Z | 12 |
| 91 | Wu et al. ²² | RCS | Taiwan | LI-2, L2-3, L3-4, | TELD | 41 (70.7) | 56.7 | 14/27 | 46.67 ± 13.36 | 2.29 ± 1.66 | 2.29 ± 1.76 | 75.6 |
| | | | | L4-5, L5-SI | IELD | 17 (29.3) | 55.2 | 6/11 | 46.24 ± 13.2 | 2.34 ± 1.7 | 2.34 ± 1.76 | 68.4 |
| 17 | Yan et al. ²³ | RCS | China | L5-SI | TELD | 84 (54.9) | 45.31 ± 11.95 | 49/35 | 63.98 ± 11.41 | 6.13 ± 1.38 | ٩N | 24 |
| | ; | | | | IELD | 69 (45.I) | 46.74 ± 11.81 | 37/32 | 60.11 ± 12.73 | 6.48 ± 1.28 | ٩Z | 24 |
| 8 | Yin et al. ²⁴ | RCS | China | L3-4, L4-5, L5-SI | TELD | 44 (51.2) | 34.58 ± 6.7 | 34/10 | 58.31 ± 4.58 | 8.07 ± .76 | ٩Z | 26.4 |
| | | | | | IELD | 42 (48.8) | 34.72 ± 7.12 | 28/14 | 57 ± 3.7 | 8.14 ± .78 | ٩Z | 26.4 |

Table 1. Characteristics of the Included Studies.

Table 2. Quality Assessment of Included Nonrandomized Studies inthe Meta-Analysis According to Newcastle-Ottawa QualityAssessment Scale.

| Study | Selection | Comparability | Outcome | Total score |
|-------------------------------|-----------|---------------|---------|-------------|
| Bamrungthin ¹¹ | 3 | 2 | 2 | 7 |
| Chen et al. ²⁶ | 3 | 2 | 2 | 7 |
| Cheng et al. ¹² | 3 | 2 | 3 | 8 |
| Choi et al. ²⁵ | 3 | 2 | 3 | 8 |
| Choi et al. ¹³ | 3 | 2 | 3 | 8 |
| Gao et al. ¹⁴ | 3 | 2 | 2 | 7 |
| Huang et al. ¹⁵ | 3 | 2 | 3 | 8 |
| Jiang et al. ¹⁶ | 3 | 2 | 2 | 7 |
| Liu et al. ¹⁷ | 3 | 2 | 2 | 7 |
| Mlaka et al. ²⁷ | 3 | 2 | 3 | 8 |
| Rajamani et al. ²⁰ | 3 | 2 | 3 | 8 |
| Sebben et al. ²⁸ | 3 | 2 | 2 | 7 |
| Wei et al. ²¹ | 3 | 2 | 2 | 7 |
| Wu et al. ²² | 3 | 2 | 3 | 8 |
| Yan et al. ²³ | 3 | 2 | 3 | 8 |
| Yin et al. ²⁴ | 3 | 2 | 3 | 8 |

 Table 3. Risk of Bias Assessment of Included Randomized

 Controlled Studies According to the Cochrane Collaboration Tool.

| Study | Nie et al. ¹⁹ | Mo et al. ¹⁸ |
|--|--------------------------|-------------------------|
| Random sequence generation | Low | Low |
| Allocation concealment | Unclear | Unclear |
| Blinding of participants and personnel | Low | Low |
| Blinding of outcome assessment | Unclear | Unclear |
| Incomplete outcome data | Low | Low |
| Selective reporting | Low | Low |
| Other bias | Low | Low |

among the included studies and the fixed-effect model was used. Among the included studies, there was no significant difference of preoperative ODI (MD = .16; 95% CI = -.82-1.14; P = .75) and VASL (MD = -.06; 95% CI = -.20-.08; P = .32), however, preoperative VASB was significantly higher in TELD group (MD = .25; 95% CI: .07-.42; P = .006).

Perioperative Data

Operative Time

There were 14 studies that reported operative time, including 1586 patients with 801 and 785 patients in TELD and IELD groups, respectively.¹¹⁻²⁴ The random effect model was used for comparison since the heterogeneity was high (P < .00001, $I^2 = 98\%$). As depicted in Figure 2A, comparative results revealed significant differences in surgical duration between the 2 approaches. TELD tended to have significantly longer operative time than IELD group. (MD = 10.1 min; 95% CI: 1.925-18.77; P < .00001). However, subgroup analysis

indicated that LDH at the L5-S1 level had a significant effect on operative time. We found that TELD for L5-S1 LDH significantly required longer operative time (MD = 18.43 mins; 95% CI: 6.63-30.2; P = .002), while operation at other levels did not demonstrate a significant difference in surgical duration.

Estimated Blood Loss

As shown in Figure 2B, the estimated blood loss during the surgery was reported in only 4 studies including 564 patients.^{12,16,20,21} The test for heterogeneity revealed no significant heterogeneity existed (P = .12, I² = 48%) and the fixed-effect model was used. TELD group demonstrated statistically significantly higher blood loss than participants in the IELD (MD = 1.21 ml; 95% CI: .1-2.32; P = .03).

Hospital Stay and Bed Rest Time

Length of hospital stay was recorded in 10 studies, including 600 and 606 patients in TELD and IELD groups respectively.^{11-16,19-22} The test revealed that moderate heterogeneity existed ($I^2 = 56\%$; P = .01). The source of high heterogeneity was influenced by the study of Choi et al.¹³ However, data analysis revealed no significant difference in hospital stay between both groups (MD = .08 days, 95% CI: -.34-.18; P = .61) (Figure 2C).

The postoperative bed rest period was available in 5 studies, consisting of 262 and 282 patients in TELD and PELD groups, respectively.^{14,16,18,19,21} Significant heterogeneity was detected among these studies ($I^2 = 79\%$; P = .008). The source of high heterogeneity was influenced by the study of Nie et al.¹⁹ As demonstrated in Figure 2D, the comparative analysis indicated that TELD had a slightly shorter length of postoperative bed rest time than IELD with a statistically significant difference (MD = .55 h, 95% CI: -.83-.33; P < .0001).

Radiation Exposure From Fluoroscopy

A total of 8 studies documented the radiation exposure via fluoroscopy time, including 359 patients in TELD group and 355 patients in IELD group.^{12,15-19,23,24} The analysis indicated the heterogeneity was high (P < .00001, $I^2 = 92\%$) and the random effect model was used. The study by Liu et al.¹⁷ that focused on surgery of highly migrated disc herniation revealed higher fluoroscopic time in IELD than other studies and this study was the resource of heterogeneity. Different parameters of fluoroscopic use measurement were recorded among these studies so the standard mean difference (SMD) was used. Based on the comparison, the fluoroscopic time was significantly longer in the TELD than IELD group as illustrated in Figure 2E (SMD = 4.12; 95% CI: 3.22-5.03; P < .00001). Subgroup analysis focusing on operation for L5-S1 and other levels also demonstrated similar results.



Figure 2. Forest plot showing effect sizes and 95% CI in the perioperative data, comparing operative time (A), estimated blood loss (B), hospital stay (C), bed rest period (D) and fluoroscopy time (E) between TELD and IELD. TELD, transforaminal endoscopic lumbar discectomy; IELD, interlaminar endoscopic lumbar discectomy; SD, standard deviation; CI, confidence interval; df, degrees of freedom.

Patient-Reported Outcomes

The patient-reported outcomes improvement (ODI, VASL, VASB) was calculated from the difference of the functional scores recorded before and after the surgery. The improvement of outcomes was presented in 2 periods: at the early post-operative period and the last follow-up. The early postoperative improvement represented the short-term functional outcome following the surgery, while the last follow-up ODI represented the long-term functional outcome.

ODI

The early postoperative ODI improvement was available in 7 studies.^{12,14,18,20,22,24,25} The fixed-effect model was used since the heterogeneity was low (P = .40, $I^2 = 3\%$). As depicted in Figure 3A, the postoperative ODI improvement was significantly better following the TELD than the IELD group (MD = -1.26; 95% CI: .07-2.16; P = .04). However, the minimally clinically important difference (MCID) was not reached.

The ODI improvement at the final follow up period was available in 14 studies.^{12-16,18-24,26,27} Moderate heterogeneity was detected (P = .03, $I^2 = 46\%$) and the fixed-effect model was used. As illustrated in Figure 3B, the last follow-up ODI was not significantly different between both approaches (MD = -.32; 95% CI: -1.17-.54; P = .47). Subgroup analysis for TELD and IELD at L5-S1 level revealed similar results to operation at other levels.

VAS of Leg Pain and VAS of Back Pain

The early postoperative VASL improvement was recorded in 7 studies.^{12,18,20-22,24,25} The fixed-effect model was used since the heterogeneity was not significant (P = .09, $1^2 = 45\%$). As depicted in Figure 3C, the postoperative VASL improvement was not significantly different between 2 approaches (MD = -.01; 95% CI: -.19-.16; P = .89).

At the last follow-up, the VASL improvement was available in 12 studies.^{12,14,15,18-24,26,27} Moderate heterogeneity was detected (P = .004, $I^2 = 60\%$) and the random-effect model was used. The source of heterogeneity was from Huang et al.¹⁵ As illustrated in Figure 3D, the last follow-up VASL was not significantly different between both approaches (MD = .16; 95% CI: -.06-.38; P = .15) (Fig. 3D).

For VASB, the comparison in the early postoperative period was recorded in only 3 studies.^{20,22,25} The results showed low heterogeneity among the included studies (P = .28, $I^2 = 22\%$), thus the fixed-effect model was used. The early postoperative VASB reduction was significantly better in TELD than IELD group (MD = -.23; 95% CI: -.40 to -.05; P = .01), as shown in Figure 3E. However, the MCID for VASB reduction between both techniques was not reached.

VASB at the final follow-up was available in 5 studies.^{15,16,20,22,27} No obvious heterogeneity was detected

(P = .12, $I^2 = 46\%$) and the fixed-effect model was used. Likewise, VASB reduction at the final follow-up was significantly better following TELD than IELD group (MD = -.25; 95% CI: -.41 to -.09; P = .002), as shown in Figure 3F. Similarly, the MCID of VASB reduction was not reached.

Patient Satisfaction

Patient satisfaction was classified by the MacNab evaluation which was recorded in 7 studies, including 291 and 288 patients in TELD and IELD group, respectively.^{12,15,17-19,21,22} The rate of patient satisfaction postoperatively was relatively high for both groups. The MacNab criteria were assigned to be "excellent" or "good" for over 80% of the participants following TELD and IELD in all included studies. However, there were no statistically significant differences between the 2 approaches (RR = .93; 95% CI: .91-1.01; P = .15), and the fixed-effect model was used as there was no heterogeneity (P = .96, I² = 0%) as demonstrated in Figure 3G.

Complications

There were 9 studies which recorded the complications, as illustrated in Figure 4A.^{12,17-21,23,27,28} The overall complication rates were relatively low with approximately 11.8% in TELD and 11.2% in IELD group, except for the study by Mlaka et al.²⁷ which reported higher complication rates in both groups, 15.5% and 18.1% in TELD and IELD group, respectively. The fixed-effect model was performed for the analysis due to the low heterogeneity (P = .87, $I^2 = 0$ %). The overall complication rates were not significantly different between the TELD and IELD groups (OR = 1.03; 95% CI: .70-1.52; P = .88).

Rates of recurrent disc herniation were recorded in 7 studies with average rates of 5.8% and 6.4% following TELD and IELD, respectively.^{15,19-21,25,27,28} The heterogeneity was low (P = .92, $I^2 = 0$) and the fixed-effect model was used. There was no significant difference of rates of recurrence following the surgery between the TELD and IELD groups (RR = .92; 95% CI: .92-1.57; P = .77), as illustrated in Figure 4B.

Rates of dural tear were available in 6 studies.^{17,18,20,26-28} The average rates dural tear were 1.3% and 2.1% following TELD and IELD, respectively. The heterogeneity was low (P = .88, $I^2 = 0$) and the fixed-effect model was used. Also, there were no significant differences in rates of dural tear between both techniques (RR = .64; 95% CI: .22-1.88; P = .41), as illustrated in Figure 4C.

Publication Bias

Risk of bias assessment was performed through the funnel plot and Egger's test, indicating that low risks of bias were detected among the included studies. All the funnel plots were

| Α | | TELD | | | | | | | Mean Differe | 000 | Mean Difference |
|---|--|---|---|--|---|---|---|--|--|--------------|--|
| Study or Subgroup | Mean | TLLD | SD To | tal Me | an | | SD Total | Weight | IV, Fixed, 9 | 5% CI | IV, Fixed, 95% Cl |
| Cheng 2022 | -68.12 | | 9.9 | 26 -67. | 83 | 8.8 | 74 28 | 5.6% | -0.29 [-5.32, | 4.74] | |
| Choi 2013 | -40 | 13 | .68 | 30 -36 | 6.5 | 15. | 68 30 | 2.6% | -3.50 [-10.95] | 3.95] | |
| Gao 2021 | -18.71 | 15 | 1.78 | 38 -20. | 54 | 15. | 72 38 | 2.8% | 1.83 [-5.25, | 8.91] | |
| Mo 2019 Rejement 2021 | -59.26 | 8.5 | 933 | 39 -61. | 59 40 | 1.1 | 03 41 | 10.6% | 2.33 [-1.33, | 5.99] | |
| Kajamani 2021 Võu 2021 | -07.12 | 10 | 552 | 80 -54. 41 -1 | 49 06 12 | 751568 | 69 60 53 17 | 2.8% | -2.03 (-5.80, | 7 351 | |
| Yin 2021 | -32.29 | 3.9 | 969 | 44 -30. | 52 | 3.2 | 23 42 | 61.4% | -1.77 [-3.29, | -0.25] | |
| | | | | | | | | | | | |
| Total (95% CI) | | | 3 | 04 | | | 282 | 100.0% | -1.26 [-2.46, | 0.07] | · · · · • |
| Heterogeneity: Chi ² = 8 | 6.21, df = 6 | (P = 0.4) | 0); I ² = 3 | % | | | | | | | -10 -5 0 5 10 |
| lest for overall effect: 2 | 2 = 2.07 (P = | = 0.04) | | | | | | | | | Favours [TELD] Favours [IELD] |
| | | | | | | | | | | | |
| В | | TELD | | | IELD | | | Mean | Difference | | Mean Difference |
| Study or Subgroup | Mean | SD | Total | Mean | S | D Tota | l Weight | t IV,I | ixed, 95% C | | IV, Fixed, 95% CI |
| Chen 2019 | -49.5 | 14.95 | 27 | -48 | 13.2 | 2 13 | 3 0.9% | -1.50 | [-10.63, 7.63] | | |
| Cheng 2022 | -53.31 | 8.91 | 26 | -54.29 | 7.96 | 6 2 | 8 3.6% | 5 0.98 | 3 [-3.54, 5.50] | | |
| Gao 2021 | -52.04 | 14.49 | 38 | -53.47 | 13.6 | 7 3 | 8 1.8% | 5 1.43 | 3 [-4.90, 7.76] | | |
| Huang 2021 | -56 | 5.59 | 37 | -55.75 | 5.57 | 5 41 | 0 11.8% | o -0.25 | 5 [-2.75, 2.25] | | |
| Jiang 2018 | -38.5 | 13.46 | 68 | -39.4 | 15.7 | 3 /1 | 8 3.3% | 0.90 | J [-3.84, 5.64] | | |
| KC Chul 2019 Miaka 2020 | -40.2 | 10.2 | 10/ | -41 | 16.4 | 1 13. | 2 5.2% | 0.8L | 12 72 44 25 | | |
| Maka 2020 Mo 2019 | -21.07 | 0.00 | 103 | -20.01 | 763 | 7 8. 6 4. | 5 3.9% 1 EEN | 2 7.04 | [2.73, 11.35] 51.1.21 (0.04) | | |
| Nio 2018 | -01.90 | 0.90 | 20 | -03.91 | 120 | 0 4 6 2 | 1 0.0% N 1.70/ | 2.35 | 1 6 09 7 00 | | |
| Rejamani 2021 | -30.1 | 9 72 | 90 | -30.0 | 11 | 0 JI 1 DI | 6 7.60 | , 0.00 | 16542 0.00 | | |
| Vajamani 2021 Valei 2021 | -40.8 | 82 | 87 | -41.2 | 674 | 5 10 | 5 15.8% | 0.40 |) [-3.42, 0.02]) [-1 75 2 55] | | |
| Wu 2021 | -40.21 | 12 | 41 | -39.94 | 11.8 | 7 1 | 7 16% | -0.27 | 7 -7 00 6 46 | | |
| Yan 2020 | -42.51 | 9.92 | 84 | -38.1 | 11.0 | 5 6 | 9 6.5% | -4.41 | 1-7.771.05 | | |
| Yin 2021 | -38.31 | 4.03 | 44 | -36.95 | 3.2 | 2 4 | 2 31.0% | -1.36 | 6 1-2.90. 0.18 | | |
| | | | | | | | | | | | |
| Total (95% CI) | | | 867 | | | 802 | 2 100.0% | -0.32 | [-1.17, 0.54] | | • |
| Heterogeneity: Chi ² : | = 24.02, dt | f=13 (F | P = 0.03 | 3); I ² = 41 | 6% | | | | | 1 | |
| | . 7 0 70 | | | | | | | | | | |
| Test for overall effect | L Z = 0.72 | (P = 0.4 | 47) | | | | | | | | Favours [TELD] Favours [IELD] |
| Test for overall effect | t. Z = 0.72 | (P = 0.4 | 47) | 1 | ELD | | | Mean D | ifference | | Favours [TELD] Favours [IELD] Mean Difference |
| C Study or Subgroup | t. 2 = 0.72 | (P = 0.4 TELD SD | 47) Total | Mean | IELD SD | Total | Weight | Mean D IV, Fix | ifference ed, 95% Cl | | Favours (TELD) Favours (IELD) Mean Difference IV. Fixed, 95% Cl |
| C Study or Subgroup Cheng 2022 | Mean -4.35 | (P = 0.4 TELD SD 0.81 | 47) <u>Total</u> 26 | Mean -4.68 | ELD SD 0.8 | Total 28 | Weight 16.9% | Mean D IV, Fix 0.33 (- | ifference ed, 95% Cl | | Favours (TELD) Favours (IELD) Mean Difference IV, Fixed, 95% Cl |
| C Study or Subgroup Cheng 2022 Choi 2013 | ∠= 0.72 | (P = 0.4 TELD SD 0.81 1.32 | 47) <u>Total</u> 26 30 | Mean -4.68 -5.9 | ELD SD 0.8 1.45 | Total 28 30 | Weight 16.9% 6.4% | Mean D IV, Fix 0.33 [- 0.10 [- | ifference sed, 95% Cl 0.10, 0.76] 0.60, 0.80] | | Favours (TELD) Favours (IELD) Mean Difference IV, Fixed, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 | ∠= 0.72 | (P = 0.4 TELD SD 0.81 1.32 1.13 | 47) <u>Total</u> 26 30 39 | Mean -4.68 -5.9 -3.8 | ELD SD 0.8 1.45 1.15 | Total 28 30 41 | Weight 16.9% 6.4% 12.5% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] | ifference ed, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 | Mean -4.35 -5.8 -3.28 -7.84 | (P = 0.4 TELD SD 0.81 1.32 1.13 2.59 | 47) <u>Total</u> 26 30 39 86 | Mean -4.68 -5.9 -3.8 -7.83 | ELD SD 0.8 1.45 1.15 1.48 | Total 28 30 41 86 | Weight 16.9% 6.4% 12.5% 7.9% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% Cl |
| Test for overall effect C Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 | Mean -4.35 -5.8 -3.28 -7.84 -4 | (P = 0.4 TELD SD 0.81 1.32 1.13 2.59 1.25 | 47) <u>Total</u> 26 30 39 86 87 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 | ELD SD 0.8 1.45 1.15 1.48 1.61 | Total 28 30 41 86 105 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- | ifference ed, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 | (P = 0.4 SD 0.81 1.32 1.13 2.59 1.25 1.77 | 47) <u>Total</u> 26 30 39 86 87 41 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 | ELD SD 0.8 1.45 1.45 1.45 1.45 1.48 1.61 1.76 | Total 28 30 41 86 105 17 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- -0.12 [- | ifference ed, 95% CI 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] | | Favours (TELD) Favours (IELD) Mean Difference IV, Fixed, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 -5.89 | (P = 0.4 TELD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 | 47) Total 26 30 39 86 87 41 44 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 | ELD SD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 | Total 28 30 41 86 105 17 42 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- -0.12 [- -0.23 [- | ifference ed, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] | | Favours (TELD) Favours (IELD) Mean Difference IV, Fixed, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 -5.89 | (P = 0.4 TELD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 | 47) <u>Total</u> 26 30 39 86 87 41 44 252 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 | ELD SD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 | Total 28 30 41 86 105 17 42 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- -0.12 [- -0.23 [- | ifference ed, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] | | Favours (TELD) Favours (IELD) Mean Difference IV, Fixed, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 -5.89 | (P = 0.4 TELD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 | 47) Total 26 30 39 86 87 41 44 353 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 | ELD SD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 | Total 28 30 41 86 105 17 42 349 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% | Mean D IV, Fix 0.33 [- 0.52] -0.01 [- -0.30 [- -0.32 [- -0.23 [- -0.23 [- | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] | | Favours (TELD) Favours (IELD) Mean Difference IV, Fixed, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Total (offection offection) | Mean -4.35 -5.88 -7.84 -0.16 -5.89 = 10.86, (| (P = 0.4 SD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 df = 6 (F | 47) Total 26 30 39 86 87 41 44 353 P = 0.09 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 3); ² = 4 | ELD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 5% | Total 28 30 41 86 105 17 42 349 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- -0.23 [- -0.01 [- | ifference ed, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] | | Favours (TELD) Favours (IELD) Mean Difference IV, Fixed, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect | Mean -4.35 -5.8 -3.28 -7.84 -0.16 -5.89 = 10.86, c | (P = 0.4 TELD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 df = 6 (F 4 (P = 0 | 47) <u>Total</u> 26 30 39 86 87 41 44 353 9 = 0.09 1.89) | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 3); I ² = 4 | ELD SD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 5% | Total 28 30 41 86 105 17 42 349 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- -0.23 [- -0.01 [- | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.83 0.53, 0.07] 0.19, 0.16] | - <u>-</u> 2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 Favours [TELD] Favours [IELD] |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi [≈] Test for overall effect | Mean -4.35 -5.8 -3.28 -7.84 -0.16 -5.89 = 10.86, c | (P = 0.4 TELD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 #f = 6 (F (P = 0 | 47) 26 30 39 86 87 41 44 353 9 = 0.0! (.89) | <u>Mean</u> -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 3); I² = 4 | ELD <u>SD</u> 0.8 1.45 1.45 1.48 1.61 1.76 0.76 5% | Total 28 30 41 86 105 17 42 349 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.30 [-0.23 [-0.23] -0.01 [- | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 0.70, 0.10] 0.53, 0.07] 0.19, 0.16] | -2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 Favours [TELD] Favours [IELD] |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect | Mean -4.35 -5.8 -3.28 -7.84 -0.16 -5.89 = 10.86, c | (P = 0.4 TELD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 df = 6 (F (P = 0) | 47) Total 26 30 39 86 87 41 44 353 P = 0.09 0.89) | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 ∂); I² = 4 | ELD 50 0.8 1.45 1.15 1.48 1.61 1.76 0.76 5% | Total 28 30 41 86 105 17 42 349 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- -0.23 [- -0.01 [- Mean D | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.83 0.53, 0.07] 0.19, 0.16] ifference | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 Favours [TELD] Favours [IELD] Mean Difference |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi [⊉] Test for overall effect D Study or Subgroup | Mean -4.35 -5.8 -3.28 -7.84 -0.16 -5.89 = 10.86, c ct: Z = 0.14 | (P = 0.4 SD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 df = 6 (F 4 (P = 0) FELD SD | 47) Total 26 30 39 86 87 41 44 353 P = 0.09 1.89) Total | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 3); ² = 4 Mean | ELD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 5% ELD SD | Total 28 30 41 86 105 17 42 349 349 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% Weight | Mean D IV, Fix 0.33 [- 0.10 [- 0.52] -0.01 [- -0.30 [- -0.23 [- -0.01 [- Mean D IV, Rand | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference iom, 95% Cl | H | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 0 1 2 Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Chen 2019 | Mean -4.35 -5.8 -7.84 -7.84 -7.84 -7.84 -7.84 -4 -0.16 -5.89 = 10.86, 0 ct: Z = 0.14 Mean -6.2 | (P = 0.4 TELD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 df = 6 (F df = 6 (F SD 1.47 | 47) Total 26 30 86 87 41 44 353 9 = 0.05 (.89) Total 27 27 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 3); ² = 4 Mean -5 -5 | ELD SD 0.8 1.45 1.45 1.45 1.45 1.45 1.45 0.76 5% ELD SD 1.31 | Total 28 30 41 86 105 17 42 349 70 13 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% Weight 4.2% | Mean D IV, Fix 0.33 [0.10 [-0.20] -0.23 [-0.23] -0.01 [- Mean D IV, Rand -0.20] | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference lom, 95% Cl [-1.10, 0.70] | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Chen 2019 Chen 2019 Chen 2022 | Mean -4.35 -5.8 -7.84 -7.84 -7.84 -7.84 -4 -0.16 -5.89 = 10.86, c ct: Z = 0.14 Mean -5.2 -5.2 -5.2 -5.2 | (P = 0.4 SD 0.81 1.32 1.32 1.25 1.77 0.67 4f = 6 (F SD 1.47 0.79 1.47 0.79 | 47) Total 26 30 39 86 87 41 44 353 2 = 0.09 Total 27 26 6 27 26 6 27 26 6 27 26 6 27 26 6 27 26 27 26 27 26 20 29 20 20 20 20 20 20 20 20 20 20 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 3); ² = 4 Mean -5 -6.18 -5 | ELD SD 0.8 1.45 1.45 1.45 1.45 1.45 1.45 0.76 5% ELD SD 1.31 0.79 | Total 28 30 41 86 105 17 42 349 70tal 13 28 28 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% Weight 4.2% 9.6% | Mean D 1V, Fix 0.33 (0.10 (0.52 (-0.01 (-0.23 (-0.01 (| ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference imp. 95% CI [-1.10, 0.70] [-0.13, 0.71] 0.51, 0.21] | - <u>-</u> 2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 0 1 2 Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Chen 2019 Chen 2019 Chen 2022 Gao 2021 | Mean -4.35 -5.8 -3.28 -7.328 -7.64 -0.16 -5.89 = 10.86, 0 ct: Z = 0.14 1 Mean -5.2 -5.89 -5.97 | (P = 0.4 SD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 df = 6 (F FELD SD 1.47 0.79 0.89 | Total 26 30 39 86 87 41 44 353 2 = 0.09 889) Total 27 26 38 38 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 30; I ² = 4 II Mean -5 -6.18 -5.86 | ELD SD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 5% ELD SD 1.31 0.79 0.88 | Total 28 30 41 86 105 17 42 349 Total 13 28 38 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% Weight 4.2% 9.6% 10.0% | Mean D IV, Fix 0.33 [0.52] -0.01 [-0.30 [-0.23 [-0.01 [- Mean D IV, Rand -0.20 0.29 -0.11 | ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference iom, 95% CI [-1.10, 0.70] [-0.13, 0.71] [-0.51, 0.29] 0.50, 0.422 | ŀ | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% Cl -1 Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Cheng 2022 Gao 2021 Huang 2021 Malei 2022 | Mean -4.35 -5.8 -7.84 -7.84 -4 -0.16 -5.89 = 10.86, 0 :t: Z = 0.14 Mean -5.2 -5.89 -5.97 -5.2 | $\begin{array}{c} (P=0.4\\ FELD\\ SD\\ 0.81\\ 1.32\\ 1.13\\ 2.59\\ 1.25\\ 1.77\\ 0.67\\ tf=6 (ff\\ ep=0\\ tf=0\\ 1.47\\ 0.89\\ 0.92\\ 0.89\\ 0.92\\ \end{array}$ | Total 26 30 39 86 87 41 44 353 29 = 0.09 1.89) Total 27 26 38 37 400 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 3); ² = 4 II Mean -5.66 -6.18 -5.86 -6.2 | ELD SD 0.8 1.45 1.15 1.48 1.61 1.76 0.76 5% ELD SD 1.31 0.79 0.88 0.95 0.95 | Total 28 30 41 86 105 17 42 349 Total 13 28 38 40 0 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% 9.6% 10.0% 9.6% 9.6% 10.0% 9.6% | Mean D IV, Fix 0.33 [0.52] -0.01 [-0.30 [-0.23 [-0.01 [- Mean D V, Rand -0.29 -0.11 1.00 | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference lom, 95% Cl [-1.10, 0.70] [-0.13, 0.71] [-0.51, 0.29] [0.58, 1.42] (0.97, 0.42] | - <u>-</u> 2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Cheng 2019 Cheng 2022 Gao 2021 Huang 2021 Mlaka 2020 Ma 2010 | Mean -4.35 -5.8 -3.28 -7.84 -0.16 -5.89 = 10.86, 0 :t: Z = 0.14 Mean -6.2 -5.89 -5.2 | (P = 0.4 (P = 0.4)) = 0.81 (P = 0.4) (P = 0.4) (P = 0.4) (P = 0.8) (P = 0.8) (P = 0.6) (P = 0. | 47) Total 26 30 39 86 87 41 44 353 22 = 0.09 .89) Total 27 26 38 37 103 37 | Mean -4.68 -5.9 -7.83 -3.7 -5.66 3); I ² = 4 II Mean -5.86 -5.86 -6.2 -6.2 -4.73 | ELD SD 0.8 1.45 1.45 1.45 1.46 1.76 0.76 5% ELD SD 0.79 0.88 0.95 2.06 | Total 28 30 41 86 105 17 42 349 Total 13 28 38 38 40 83 | Weight 16.9% 6.4% 12.5% 7.9% 3.2% 34.0% 100.0% Weight 4.2% 9.6% 7.1% 9.6% 7.1% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.23 [-0.23 [-0.23 [-0.01 [- Mean D V, Rand -0.20] 0.29 -0.11 1.00 -0.38 -0.38 | ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference ifference iom, 95% CI (-1.13, 0.71] (-0.51, 0.29] [0.58, 1.42] (-0.45, 0.27] | ŀ | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wu 2021 Yin 2021 Total (95% Cl) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Cheng 2022 Gao 2021 Huang 2021 Mlaka 2020 Mo 2019 Nie 2019 | $\frac{Mean}{-4.35}$ -4.35 -5.8 -7.84 -7.84 -4 -0.16 -5.89 = 10.86, (c) t: Z = 0.14 Mean -5.2 -5.89 -5.9 -5.9 -5.9 -5.9 -5.9 | (P = 0.4) FELD SD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 FELD SD 1.47 0.79 0.89 0.92 2 1.02 2 1.02 2 1.02 2 1.02 2 1.02 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | 47) Total 26 30 39 86 87 41 44 353 2° = 0.0! .89) Total 27 26 38 37 103 39 20 20 20 20 20 20 20 20 20 20 | Mean -4.68 -5.9 -7.83 -7.83 -3.7 -0.04 -5.66 3); ² = 4 II Mean -5 -6.18 -6.18 -6.2 -6.2 -4.73 -5.36 | ELD 0.8 1.45 1.45 1.45 1.45 1.45 1.48 1.61 0.76 5% ELD SD 1.31 0.79 SD 0.88 0.95 2.06 0.99 1.4 | Total 28 30 41 86 105 17 42 349 Total 13 28 38 83 840 83 83 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% Weight 4.2% 9.6% 10.0% 9.6% 7.1% 9.6% 7.1% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.23 [-0.23 [-0.23 [-0.01 [- Mean D IV, Rand -0.20 0.29 -0.11 1.00 -0.38 0.29 0.42 | ifference ied, 95% Cl 0.10, 0.76] 0.60, 0.80] (0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference ifference ifference ifference 007, 95% Cl [-1.10, 0.70] [-0.51, 0.29] [0.58, 1.42] [-0.57, 0.21] [-0.51, 0.73] [-0.51, 0.73] [| - <u>-</u> 2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI -1 0 2 Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Chen 2019 Chen 2022 Gao 2021 Huang 2021 Miaka 2020 Mo 2019 Nie 2016 Painerei 2021 | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 -5.89 ct: Z = 0.14 1 Mean -5.2 -5.11 -5.22 -5.11 -5.02 -5.3 | (P = 0.4) $(P = 0.4)$ $(P = 0.4)$ $(P = 0.4)$ $(P = 0)$ $(P = 0$ | 47) Total 26 30 39 86 87 41 44 353 5 = 0.0(.89) Total 27 26 38 37 103 39 300 6 6 7 103 39 30 6 6 7 103 39 30 6 6 7 10 10 10 10 10 10 10 10 10 10 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 -6.18 -5.86 -6.18 -5.83 -5.83 -6.2 -4.73 -5.31 -5.70 | ELD SD 0.8 1.45 1.45 1.48 1.61 1.76 5% ELD SD 1.31 0.79 0.88 0.95 2.06 0.99 1.4 4.62 1.42 1.75 1.48 1.75 1.48 1.75 1.46 | Total 28 30 41 105 17 42 349 Total 13 28 38 40 83 40 83 41 300 65 | Weight 16.9% 6.4% 12.5% 7.9% 32.% 34.0% 100.0% Weight 4.2% 9.6% 9.6% 9.6% 7.1% 9.3% 6.1% | Mean D 1V, Fix 0.33 [0.52] -0.01 [-0.30 [-0.23 [-0.01 [-0.01 [-0.20 [0.29] -0.11 1.000 -0.38 0.29 0.40 0.40 | ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference imp. 95% CI [-1.10, 0.70] [-0.13, 0.71] [-0.58, 1.42] [-0.97, 0.21] [-0.57, 1.07] [-0.27, 1.07] [-0.49, 0.49] | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% Cl -1 0 1 2 Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Chen 2019 Chen 2019 Cheng 2022 Gao 2021 Huang 2021 Mlaka 2020 Mo 2019 Nie 2016 Rajamani 2021 Wei 2021 | $\begin{array}{c} \mathbf{Mean} \\ -4.35 \\ -5.8 \\ -3.28 \\ -7.84 \\ -4 \\ -0.16 \\ -5.89 \\ \end{array}$ $= 10.86, 0 \\ \text{ct: } Z = 0.14 \\ \begin{array}{c} \mathbf{Mean} \\ -5.2 \\ -5.89 \\ -5.97 \\ -5.2 \\ -5.11 \\ -5.02 \\ -5.3 \\ -8.02 \\ -5.3 \\ -8.02 \\ -5.5 \end{array}$ | f(P = 0.4) $f(P = 0.4)$ $f(P = 0.4)$ $f(P = 0)$ $f(P$ | 47) Total 26 30 39 86 87 41 44 353 2 = 0.03 889) Total 27 26 38 37 103 39 30 86 87 41 44 55 55 55 56 57 56 57 56 57 56 57 57 57 57 57 57 57 57 57 57 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 30; I ² = 4 Mean -5 -6.18 -6.28 -6.28 -6.28 -6.23 -5.31 -5.7 -8.19 -5.9 -8.86 -5.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -7.83 -6.9 -6.9 -6.9 -6.9 -7.83 -7.83 -6.9 -6.9 -6.9 -6.9 -7.83 -7.83 -6.9 -6.7 -6.7 -6.7 -6.9 -6.7 -7.7 - | ELD 0.8 1.45 1.45 1.45 1.46 1.76 0.76 5% ELD 5% ELD 5% ELD 2.06 0.99 1.4 1.48 1.91 1.91 1.91 1.91 1.91 1.92 1.93 1.93 1.95 1 | Total 28 30 41 86 105 17 42 349 Total 13 28 38 40 83 41 30 86 81 105 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% 9.6% 10.0% 9.6% 10.0% 9.6% 10.0% 9.6% 1.1% 6.4% 6.4% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.23 [-0.23 [-0.01 [-0.20] 0.29 -0.11 1.00 0.29 0.40 0.29 0.40 0.17 0.20 | ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference iom, 95% CI [-1.10, 0.70] [-0.51, 0.29] [0.55, 1.42] [-0.97, 0.21] [-0.97, 0.21] [-0.97, 0.21] [-0.97, 1.07] [-0.94, 0.82] [-0.97, 1.07] [-0.94, 0.82] [-0.95, 0.441] [-0.95, 0.451] [-0.95, 0.451] [-0.95, 0.451] [| | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% Cl |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Chen 2019 Chen 2019 Chen 2021 Muaka 2020 Mo 2019 Nie 2016 Rajamani 2021 Wei 2021 Wei 2021 | $\begin{array}{c} \textbf{Mean} \\ -4.35 \\ -5.8 \\ -7.84 \\ -4.4 \\ -0.16 \\ -5.89 \\ = 10.86, c \\ t: Z = 0.14 \\ \hline \textbf{Mean} \\ -5.2 \\ -5.89 \\ -5.97 \\ -5.2 \\ -5.11 \\ -5.02 \\ -5.3 \\ -8.02 \\ -5.8 \\ $ | (P = 0.4 FELD SD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 FELD SD 1.47 0.79 0.89 0.92 2 1.02 1.25 2.69 1.02 1.25 1.47 0.79 0.92 1.25 1.47 0.79 0.92 1.25 1.47 0.79 0.92 1.25 1.47 0.79 0.92 1.47 0.47 1.47 0.47 1.47 1.47 1.47 1.77 0.67 FELD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD | 47) Total 26 30 39 86 87 41 44 353 2=0.09 889) Total 27 26 38 37 103 39 30 86 87 41 44 44 27 26 38 37 103 27 26 38 38 41 44 44 44 44 44 44 44 44 44 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -0.04 -5.66 30; I ² = 4 Mean -5 -6.18 -5.86 -6.18 -5.86 -6.2 -4.73 -5.31 -5.51 -5.19 -5.61 -5.19 | ELD 0.8 1.45 1.45 1.45 1.48 1.61 1.76 0.76 5% ELD 5% ELD 0.98 0.95 2.06 0.99 1.4 1.48 1.13 1.51 | Total 28 30 41 86 105 17 42 349 Total 13 28 38 40 83 84 30 83 41 30 86 105 17 | Weight 16.9% 6.4% 12.5% 7.9% 32.% 32.% 34.0% 100.0% 9.6% 10.0% 9.6% 10.0% 9.6% 10.0% 9.3% 6.1% 6.4% 11.5% 9.3% 6.4% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.30 [-0.23 [-0.01 [| ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.70, 0.10] 0.70, 0.10] 0.53, 0.07] 0.19, 0.16] ifference iom, 95% CI [-1.10, 0.70] [-0.13, 0.71] [-0.51, 0.29] [0.58, 1.42] [-0.97, 0.21] [-0.15, 0.73] [-0.27, 1.07] [-0.48, 0.82] [-0.51, 0.10] | -2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% CI Mean Difference IV, Random, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Chen 2019 Cheng 2022 Gao 2021 Huang 2021 Mlaka 2020 Mo 2019 Nie 2016 Rajamani 2021 Wei 2021 Wei 2021 Wei 2021 Wei 2021 Wei 2021 Wei 2021 | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 -5.89 ett Z = 0.14 1 Mean 1 Mean -5.89 -5.97 -5.2 -5.11 -5.3 -8.02 -5.3 -8.02 -5.8 -1.85 | (P = 0.4 FELD SD 0.81 1.32 1.13 2.59 1.25 1.77 0.67 FELD SD 1.47 0.79 0.92 2 2 1.02 | 47) Total 26 30 39 86 87 41 44 353 2° = 0.09 889) Total 27 26 38 37 103 39 86 87 41 44 88 37 103 39 86 87 41 44 88 88 88 88 88 88 88 88 88 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -5.66 -0.1 -5.66 -6.18 -5.86 -6.2 -6.7 -6.18 -5.86 -6.2 -5.31 -5.7 -8.19 -5.6 | ELD 0.8 1.45 1.45 1.45 1.45 1.46 0.76 5% ELD 5% ELD 5% 5% 5% 5% 5% 1.31 0.79 0.88 0.95 2.06 0.99 1.44 1.41 1.31 1.51 1.42 1.75 1.45 1.76 1.77 | Total 28 30 41 86 105 17 42 349 Total 13 88 40 83 41 30 86 105 17 60 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% 9.6% 7.1% 9.6% 7.1% 9.6% 10.0% 9.6% 11.5% 4.6% 11.5% 4.6% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.30 [-0.23 [-0.01 [-0.01 [-0.23 [-0.01 [-0.02 [-0.01 [| ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference lom, 95% CI [-1.10, 0.70] [-0.13, 0.71] [-0.51, 0.29] [0.58, 1.42] [-0.51, 0.73] [-0.27, 1.07] [-0.48, 0.82] [-0.51, 0.11] [-0.80, 0.90] [-0.23, 0.67] | -2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Cheng 2019 Cheng 2022 Gao 2021 Huang 2021 MIaka 2020 Mo 2019 Nie 2016 Rajamani 2021 Wei 2021 Wei 2021 Wei 2021 Yan 2020 Yin 2021 | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 -5.89 = 10.86, 0 :t: Z = 0.14 Mean -6.2 -5.97 -5.2 -5.11 -5.22 -5.11 -5.23 -8.02 -5.8 -1.85 -4.98 -6.58 | $(P = 0.4 \\ (P = 0.4 \\ SD \\ 0.81 \\ 1.32 \\ 1.13 \\ 2.59 \\ 1.25 \\ 1.77 \\ 0.67 \\ 1.77 \\ 0.67 \\ 1.77 \\ 0.67 \\ 1.77 \\ 0.67 \\ 1.44 \\ 0.92 \\ 2.2 \\ 1.06 \\ 1.47 \\ 1.24 \\ 1.26 \\ 2.69 \\ 1.06 \\ 1.47 \\ 1.24 \\ 0.69 \\ 0.$ | 47) Total 26 30 39 86 87 41 44 353 27 26 38 37 103 39 30 86 87 41 103 39 41 44 44 44 44 44 44 44 44 44 | Mean -4.68 -5.9 -7.83 -7.83 -3.7 -5.66 3); I ² = 4 II Mean -5.86 -6.2 -6.7 -6.7 -6.79 -5.19 -5.66 -1.19 -5.67 | ELD 0.8 1.45 1.45 1.45 1.46 1.76 0.76 5% ELD 5% ELD 0.99 0.88 0.95 2.06 0.99 0.88 0.95 2.06 0.99 1.41 1.43 1.51 1.41 1.76 0.77 0.78 0.79 0.88 0.99 0.44 1.43 1.51 0.77 0.77 0.79 0.77 0.77 0.77 0.79 0.77 0. | Total 28 30 41 86 105 17 42 349 Total 13 88 40 83 40 83 40 83 41 105 17 69 42 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% 9.6% 7.1% 9.6% 7.1% 9.6% 7.1% 9.6% 7.1% 9.6% 11.5% 4.6% 9.9% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.23 [-0.23 [-0.23 [-0.23 [-0.21] Mean D V, Rand -0.20 0.29 0.40 0.29 0.40 0.17 -0.20 0.5 0.17 -0.20 0.5 0.17 -0.20 | ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference iffe | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Cheng 2019 Cheng 2022 Gao 2021 Huang 2021 MIaka 2020 Mo 2019 Nie 2016 Rajamani 2021 Wei 2021 Wei 2021 Wei 2021 Yan 2020 Yin 2021 | $\begin{array}{c} \textbf{Meam} \\ -4.35 \\ -5.8 \\ -3.28 \\ -7.84 \\ -4 \\ -0.16 \\ -5.89 \\ = 10.86, c \\ t: Z = 0.14 \\ \hline \textbf{Meam} \\ -5.2 \\ -5.89 \\ -5.2 \\ -5.89 \\ -5.2 \\ -5.11 \\ -5.02 \\ -5.3 \\ -8.02 \\ -5.8 \\ -1.85 \\ -4.98 \\ -6.55 \end{array}$ | $(P = 0.4 \\ FELD \\ SD \\ 0.81 \\ 1.32 \\ 1.13 \\ 2.59 \\ 1.25 \\ 1.77 \\ 0.67 \\ ff = 6 (F \\ 0.79 \\ 0.67 \\ 1.47 \\ 0.79 \\ 0.92 \\ 2 \\ 1.02 \\ 2.69 \\ 1.06 \\ 1.47 \\ 1.24 \\ 0.69 \\ 0.92 \\ 0.92 \\ 1.25 \\ 2.69 \\ 1.47 \\ 1.24 \\ 0.69 \\ 0.91 \\ 0.9$ | Total 26 30 39 86 87 41 44 353 2 0.09 889 8 8 7 103 37 103 39 30 86 87 41 84 44 44 44 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -5.66 3); I² = 4 II Mean -6.7 -5.66 -6.2 -6.7 -5.86 -6.2 -4.73 -5.81 -5.61 -6.7 -8.19 -5.61 -5.15 -6.76 | ELD 0.8 1.45 1.15 1.48 1.61 0.76 5% ELD 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 1.31 0.79 0.88 0.95 2.06 0.99 1.4 1.48 1.13 1.51 1.27 0.73 | Total 28 30 41 86 105 17 42 349 Total 13 88 40 83 40 83 41 30 86 105 17 69 42 | Weight 16.9% 6.4% 12.5% 7.9% 3.2% 34.0% 100.0% 9.6% 7.1% 9.6% 7.1% 9.6% 7.1% 9.6% 7.1% 9.6% 7.1% 9.6% 7.1% 9.6% 11.5% 4.6% 9.9% 11.7% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.23 [-0.23 [-0.23 [-0.23 [-0.21] Mean D V, Rand -0.20 0.29 0.40 0.29 0.40 0.17 -0.20 0.05 0.17 0.21 | ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference iom, 95% CI [-0.13, 0.71] [-0.51, 0.29] [0.58, 1.42] [-0.57, 0.21] [-0.58, 1.42] [-0.57, 0.21] [-0.58, 0.82] [-0.51, 0.11] [-0.48, 0.82] [-0.51, 0.11] [-0.80, 0.90] [-0.23, 0.57] [-0.09, 0.51] | -2 -2 | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI |
| Test for overall effect C Study or Subgroup Cheng 2022 Choi 2013 Mo 2019 Rajamani 2021 Wei 2021 Wu 2021 Yin 2021 Total (95% CI) Heterogeneity: Chi ² Test for overall effect D Study or Subgroup Cheng 2029 Gao 2021 Huang 2021 MIaka 2020 Mo 2019 Nie 2016 Rajamani 2021 Wei 2021 Wei 2021 Wei 2021 Wei 2021 Yan 2020 Yin 2021 Total (95% CI) | Mean -4.35 -5.8 -3.28 -7.84 -4 -0.16 -5.89 -5.89 -5.2 -6.89 -5.2 -5.11 -5.3 -8.02 -5.3 -8.02 -5.8 -1.85 -4.98 -6.55 | $(P = 0.4 \\ (P = 0.4 \\ SD \\ 0.81 \\ 1.32 \\ 1.13 \\ 2.59 \\ 1.25 \\ 1.77 \\ 0.67 \\ 1.77 \\ 0.67 \\ 1.47 \\ 0.89 \\ 0.92 \\ 2 \\ 1.25 \\ 2.69 \\ 1.06 \\ 1.47 \\ 1.24 \\ 0.69 \\ 1.47 \\ 1.24$ | Total 26 30 39 86 87 41 44 353 27 638 37 103 39 30 86 87 41 84 44 44 | Mean -4.68 -5.9 -3.8 -7.83 -3.7 -5.66 3); I ² = 4 Mean -5.66 -6.2 -6.7 -6.7 -6.7 -5.81 -5.86 -6.2 -6.7 -5.7 -5.7 -5.7 -5.7 -5.7 -5.7 -5.7 | ELD 0.8 1.45 1.45 1.45 1.46 1.76 0.76 5% ELD 5% ELD 5% 5% 5% 1.31 0.95 2.06 0.99 0.88 0.95 2.06 1.41 1.41 1.41 1.76 0.76 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% | Total 28 30 41 86 105 17 42 349 Total 13 28 38 40 83 41 30 86 105 17 69 24 2 592 | Weight 16.9% 6.4% 12.5% 7.9% 19.1% 3.2% 34.0% 100.0% 9.6% 7.1% 9.6% 7.1% 9.6% 7.1% 9.6% 11.5% 4.6% 9.9% 11.7% 10.0% | Mean D IV, Fix 0.33 [0.10 [0.52] -0.01 [-0.30 [-0.23 [-0.01 [-0.01 [-0.23 [-0.01 [-0.01 [-0.01 [-0.20] -0.20] 0.29] 0.40] 0.40] 0.41] 0.40] 0.41] 0.42] 0.44] 0. | ifference ied, 95% CI 0.10, 0.76] 0.60, 0.80] 0.02, 1.02] 0.64, 0.62] 0.70, 0.10] 1.12, 0.88] 0.53, 0.07] 0.19, 0.16] ifference [0m, 95% CI [-0.13, 0.71] [-0.51, 0.29] [0.58, 1.42] [-0.51, 0.73] [-0.51, 0.73] [-0.74, 0.82] [-0.75, 0.11] [-0.76, 0.38] -0.06, 0.38] | | Favours [TELD] Favours [IELD] Mean Difference IV, Fixed, 95% CI Favours [TELD] Favours [IELD] Mean Difference IV, Random, 95% CI Mean Difference IV, Random, 95% CI |

Figure 3. Forest plot showing effect sizes and 95% CI in the patient-reported outcomes, comparing the postoperative ODI (A), last follow-up ODI (B), postoperative VASL (C), last follow-up VASL (D), postoperative VASB (E), last follow-up VASB (F) and the MacNab excellent/good rate evaluation (G) between TELD and IELD. TELD, transforaminal endoscopic lumbar discectomy; IELD, interlaminar endoscopic lumbar discectomy; ODI, Oswestry Disability Index; VASL, visual analog scale of leg pain; VASB, visual analog scale of back pain; SD, standard deviation; CI, confidence interval; df, degrees of freedom.



Figure 3. Continued.

symmetric and the Egger's test for publication bias was not statistically significant results for all outcome variables, including operative time (P = .505), fluoroscopy time (P = .379), estimated blood loss (P = .708), length of hospital stay (P = .089), postoperative bed rest time (P = .497), ODI (P = .251), VASL (P = .986), VASB (P = .214), MacNab evaluation (P = .979), and overall complications (P = .794).

Discussion

In this study, we performed a meta-analysis of 18 high-quality evidences, including 1924 patients to compare 2 popular approaches for endoscopic lumbar discectomy: transforaminal and interlaminar approaches, in terms of perioperative data, clinical outcomes, and complications.

For the comparison of the perioperative data, IELD had shorter operative time, less estimated blood loss, and shorter fluoroscopic time. These findings were similar to the metaanalysis by He et al.²⁹ and the prospective study by Ahn et al.³⁰ that reported surgeon's radiation exposure during TELD. They

found that, within the maximum allowable dose of radiation hazard, surgeons could safely perform only 291 cases of TELD without radiation shielding. Since TELD required a more complicated puncture technique and fluoroscopic guidance for an accurate surgical trajectory with a more rigid working window, especially at L5-S1 which the high iliac crest and the narrow space to access L5-S1 foramen led to difficulty in determining the correct puncture direction and also more challenges when treating migrated LDH. In contrast to IELD at the L5-S1 level, the interlaminar space is relatively wide and most surgeons were more familiar with the anatomy when operating through posterior lumbar approach so the interlaminar approach for L5-S1 LDH was less complicated and usually required less operative time and less complicated fluoroscopic guidance.^{15,26,31} However, Wu et al.²² reported that IELD had a longer operative time than TELD when approaching for highgrade migrated LDH due to more bone resection and soft tissue work. Our study also found that TELD had a slightly shorter duration of postoperative bed rest period, according to the analysis. This finding was potentially caused by different types

| Study or Subgroup Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI Cheng 2022 2 2 2 2 3.5% 1.09 [0.14, 8.42] Lu 2017 1 31 2 7 4.1% 0.42 [0.04, 4.87] Miaka 2020 16 103 15 83 2.0% 0.83 [0.39, 1.81] Maka 2020 16 103 0.58% 0.31 [0.03, 3.7] Rajamani 2021 9 66 10 66 1.38 [0.55, 3.41] Yan 2020 12 84 9 16.9% 1.31 [0.44, 2.82] Total (95% CI) 508 498 100.0% 1.03 [0.70, 1.52] Total events 60 56 Heterogeneity: Ch ^P = 3.82, df = 8 (P = 0.87); P = 0% Total (95% CI) 508 498 100.0% 0.75% 0.50 [0.05, 5.22] Total events 60 56 56 56 56 56 Heterogeneity: Ch ^P = 3.80 178 7.5% 0.50 [0.05, 5.22] M-H, Fixed, 95% CI < | А | TELI | D | IELD |) | | Odds Ratio | | Odds Ratio | | | |
|--|---|--------------------------|--------------------|-------------------|-------|----------------|--------------------|-------------------|---|-----|---|--|
| Cheng 2022 3 5 3 2 1 3 3 2 7 1 3 2 2 1 3 4 3 4 6 3 3 1 4 6 3 3 1 4 6 3 3 1 4 4 3 3 4 3 3 4 4 3 3 4 6 1 3 1 | Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | | M-H, Fixed, 95% Cl | | | |
| Lu 2017 1 1 31 2 27 4.1% $0.42[0.04, 487]$ Miaka 2020 16 103 15 83 28.0% $0.83[0.39, 1.81]$ Mo 2019 5 33 2 41 3.4% 2267 [0.52, 15.75] Nie 2016 1 30 3 30 5.6% 0.31[0.03, 3.17] Rajamani 2021 3 24 3 31 4.6% 1.33[0.24, 7.28] Wei 2021 11 87 10 105 15.8% 1.38[0.55, 3.41] Vei 2021 11 87 10 105 15.8% 1.38[0.55, 3.41] Vei 2021 12 84 9 69 16.9% 1.11[0.44, 2.82] Total (95% CI) 508 498 100.0% 1.03[0.70, 1.52] Total events $60 - 56$ Heterogenety: Ch ² 7 3.2($d = 8(P = 0.87)$; $P = 0\%$ Testfor overall effect Z = 0.15 ($P = 0.88$) Total (95% CI) 508 498 100.0% 0.51[0.27, 207] Sebben 2021 2 37 3 40 10.9% 0.72[0.13, 4.08] Mika 2020 5 103 4 83 16.7% 1.01[0.28, 3.83] Nie 2016 0 30 1 30 5.7% 0.33[0.01, 7.87] Sebben 2021 1 24 0 31 1.37% 3.48[0.01, 7.87] Total events Ch ² 7 405 100.0% 0.72[0.13, 4.08] Total (95% CI) 397 405 100.0% 0.72[0.13, 4.08] Total (95% CI) 397 405 100.0% 0.92[0.54, 1.57] Total events 223 26 Heterogenety: Ch ² 7 2.02; $P = 0\%$ Testfor overall effect Z = 0.29; $P = 0.77$) C C Total (95% CI) 397 405 100.0% 0.92[0.54, 1.57] Total events 23 26 Heterogenety: Ch ² 7 2.02; $P = 0.9$; $P = 0.\%$ Total (95% CI) 397 405 100.0% 0.92[0.54, 1.57] Total events 243 23 C hen 2019 2 27 1 1.31 16.4% 0.96[0.10, 9.86] Lu 2017 0 31 1 27 19.5% 0.29[0.01, 6.80] Total (95% CI) 397 405 100.0% 0.92[0.54, 1.57] Total events 4 6 Heterogenety: Ch ² = 2.029; $P = 0.77$) C Total (95% CI) 310 281 100.0% 0.64[0.22, 1.88] Mika 2020 1 103 1 83 13.5% 0.310[0.01, 2.7263] Sebben 2021 1 24 2 31 26.7% 0.26[0.01, 5.10] Total (95% CI) 310 281 100.0% 0.64[0.22, 1.88] Total events 4 6 Heterogenety: Ch ² = 1.79, df = 5(P = 0.80); $P = 0\%$ Total 2021 0 24 2 31 26.7% 0.26[0.01, 5.10] Total 2021 0 24 2 231 26.7% 0.26[0.01, 5.10] Total 2021 0 | Cheng 2022 | 2 | 24 | 2 | 26 | 3.5% | 1.09 [0.14, 8.42] | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | Liu 2017 | 1 | 31 | 2 | 27 | 4.1% | 0.42 [0.04, 4.87] | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | Mlaka 2020 | 16 | 103 | 15 | 83 | 28.0% | 0.83 [0.39, 1.81] | | | | | |
| Nie 2016 1 30 3 30 5 8% 0.31 (0.03, 3.17] Rajamani 2021 9 86 10 86 17.9% 0.89 (0.34, 2.31) Setben 2021 11 87 10 105 15.8% 1.33 (0.24, 7.26) Wei 2021 11 87 10 105 15.8% 1.31 (0.24, 7.26) Total (95% CI) 508 498 100.0% 1.03 (0.70, 1.52) Total (95% CI) 508 498 100.0% 1.03 (0.70, 1.52) Total (95% CI) 508 498 100.0% 1.03 (0.70, 1.52) Total events 60 56 Heterogeneity: Chi*= 3.82, d*= 8 (P = 0.87); P = 0% Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight MH- Fixed, 95% CI M-H, Fixed, 95% CI Huang 2021 2 103 1.30 5.7% 0.33 (0.01, 7.87) 0.46 0.48 0.26 (0.25, 5.22) Huang 2021 6 8 8 0.25 (0.27, 2.07) M-H, Fixed, 95% CI Sebben 2021 1 24 0.31 1.7% 3.84 (0.16, 90. | Mo 2019 | 5 | 39 | 2 | 41 | 3.4% | 2.87 [0.52, 15.75] | | | | | |
| Bit Server is subserved by the server is se | Nie 2016 | 1 | 30 | 3 | 30 | 5.8% | 0.31 [0.03, 3.17] | | | | | |
| Sebben 2021 3 24 3 3 24 3 3 24 3 3 24 3 3 24 3 3 24 3 3 24 3 3 24 3 3 100 100 100 Total (95% CI) 508 498 100 100 Test for overall effect Z = 0.15 ($P = 0.80$) Fisk Ratio Risk Ratio Choi 201 2 7 1 100 0 Study or Subgroup Test for overall effect Z = 0.29 ($P = 0.87$); $P = 0\%$ Total (95% CI) MH, Fixed, 95% CI MH, Fixed, 95% CI MH, Fixed, 95% CI MH, Fixed, 95% CI MH at 2020 5 100 0.01 0.01 <th colspa="</td"><td>Rajamani 2021</td><td>9</td><td>86</td><td>10</td><td>86</td><td>17.9%</td><td>0.89 [0.34, 2.31]</td><td></td><td></td><td></td></th> | <td>Rajamani 2021</td> <td>9</td> <td>86</td> <td>10</td> <td>86</td> <td>17.9%</td> <td>0.89 [0.34, 2.31]</td> <td></td> <td></td> <td></td> | Rajamani 2021 | 9 | 86 | 10 | 86 | 17.9% | 0.89 [0.34, 2.31] | | | | |
| Wei 2021 11 87 10 105 15.8% 1.38 [0.55, 3.41] Yan 2020 12 84 9 69 16.9% 1.11 [0.44, 2.82] Total (95% CI) 508 498 100.0% 1.03 [0.70, 1.52] Total events 60 56 Heterogeneity: ChiP = 3.82, df = 8 (P = 0.87), P = 0% Test for overall effect Z = 0.15 (P = 0.80) Risk Ratio Risk Ratio B TELD ELD Favours [TELD] Risk Ratio Risk Ratio Mika 2020 5 103 4 9 57% 0.50 [0.05, 5.22] Huang 2021 2 37 3 40 10.9% 0.72 [0.13, 4.08] Mika 2020 5 103 6.57% 0.33 [0.01, 7.8] 9% 101 [0.28, 3.63] Nie 2016 0 397 405 100.0% 0.92 [0.54, 1.57] 9% 10 100 100 Weight MH-Fixed, 95% CI Favours [TELD] 88 76 100.0% 0.92 [0.54, 1.57] 9% 100 100 Subben 2021 8 87 105 10.4% 0.96 [0.10, 0 | Sebben 2021 | 3 | 24 | 3 | 31 | 4.6% | 1.33 [0.24, 7.28] | | · · · · · · · · · · · · · · · · · · · | | | |
| Yan 2020 12 84 9 69 16.9% 1.11 1.44 2.82 Total (95% CI) 508 498 100.0% 1.03 1.07 1.52 Total events 60 56 498 100.0% 1.03 10.70 1.52 Total events 60 56 498 100.0% 1.03 10.70 1.52 B Test for overall effect Z = 0.15 (P = 0.80) Flut Events Total Veight MH, Fixed, 95% CI Number of the test for test for the test for the test for | Wei 2021 | 11 | 87 | 10 | 105 | 15.8% | 1.38 [0.55, 3.41] | | | | | |
| Total (95% CI) 508 498 100.0% 1.03 [0.70, 1.52] Total events 60 56 Heterogeneity: Chi ^P = 3.82, df = 8 (P = 0.87); P = 0% 100 Test for overall effect Z = 0.15 (P = 0.88) Events Total Weight M-H, Fixed, 95% CI NH, Fixed, 95% CI Choi 2013 1 30 2 30 7.5% 0.50 (0.05, 6.22) Huang 2021 2 37 3 40 10.9% 0.72 (0.13, 4.08) Maka 2020 5 103 4 83 16.7% 1.01 (0.28, 3.63) Nie 2016 0 30 1 30 2.7% 0.31 (0.17, 8.7) Rajarmani 2021 8 87 8 105 27.4% 1.21 (0.47, 3.08) Total (95% CI) 397 405 100.0% 0.92 [0.54, 1.57] 0.01 0.1 10 Total (95% CI) 397 405 100.0% 0.29 [0.6, 6.12, 6.88] 0.01 0.1 10 Total (95% CI) 31 1.27 1.95% 0.26 [0.01, 6.88] 0.46 [0.10, 6.88] 0.46 [0.10, 6.88] < | Yan 2020 | 12 | 84 | 9 | 69 | 16.9% | 1.11 [0.44, 2.82] | | | | | |
| Total events 60 56 Interpretation Interpretation Interpretation Total events 60 56 Heterogeneity: Chi ^P = 3.82, df = 8 (P = 0.87); P = 0% 10 10 10 Test for overall effect Z = 0.15 (P = 0.88) Events Total Weight M-H, Fixed, 95% CI Choi 2013 1 30 2 30 7.5% 0.50 [0.05, 6.22] Huang 2021 2 37 3 40 10.9% 0.72 [0.13, 4.08] Miaka 2020 5 103 4 83 16.7% 1.01 [0.28, 3.63] Nie 2016 0 30 1 30 5.7% 0.35 [0.0.7, 8.07] Sebben 2021 1 24 0 31 1.7% 3.84 [0.16, 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% CI) 397 405 100.0% 0.92 [0.54, 1.57] 100 Favours [TELD] Events Total Events Total Weight M-H, Fixed, 95% CI Chen 2019 2 27 1 < | Total (95% CI) | | 508 | | 498 | 100.0% | 1.03 [0.70, 1.52] | | • | | | |
| Total events C TELD EVEnts Total Verige the colspan="2" colspa="">Risk Ratio <th colspa="</td" colspan="2"><td>Total events</td><td>08</td><td></td><td>56</td><td></td><td></td><td>100 [011 0, 1102]</td><td></td><td>Ť</td><td></td></th> | <td>Total events</td> <td>08</td> <td></td> <td>56</td> <td></td> <td></td> <td>100 [011 0, 1102]</td> <td></td> <td>Ť</td> <td></td> | | Total events | 08 | | 56 | | | 100 [011 0, 1102] | | Ť | |
| Test for overall effect $Z = 0.15$ ($P = 0.88$) Desting overall effect $Z = 0.15$ ($P = 0.88$) B TELD Risk Ratio Study or Subgroup Fevents Total Events Total Weight M-H, Fixed, 95% CI Choi 2013 1 30 7.5% 0.50 [0.05, 5.22] Hung 2021 2 37.5% 0.50 [0.05, 5.22] Hung 2021 2 37.5% 0.50 [0.05, 5.22] Hung 2021 2 3 10.01 M-H, Fixed, 95% CI Make 2020 5 103 4 8 30.2% 0.75 [0.27, 2.07] Sudy or Subgroup Sudy or Subgroup Site P = 0.82); P = 0% Total events 23 26 Heterogeneity: ChP = 2.01, df = 6 (P = 0.92); P = 0% Total Weight M-H, Fixed, 95% CI C Tetue Total Events | Hotorogonoity: Chiž – | 202 df- | 0 /D - | 0 0 7\· IZ - | - 0% | | | <u> </u> | | | | |
| B TELD Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI Huang 2021 2 30 7.5% 0.50 [0.05, 5.22] | Tect for overall effect: | 7-016/ | (P = 0 C | 0.07),1 - | - 0 % | | | 0.01 | 0.1 i 10 | 100 | | |
| B TELD IELD Risk Ratio Risk Ratio Risk Ratio Choi 2013 1 30 2 30 7.5% 0.50 [0.05, 5.22] Huang 2021 2 37 3 40 10.9% 0.72 [0.13, 4.08] Miaka 2020 5 103 4 83 16.7% 1.01 [0.28, 3.63] Nie 2016 0 30 1 30 5.7% 0.33 [0.01, 7.87] Rajamani 2021 6 86 8 86 30.2% 0.75 [0.27, 2.07] Sebben 2021 1 24 0 31 1.7% 3.84 [0.16, 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% CI) 397 405 100.0% 0.92 [0.54, 1.57] 100 Total events 23 26 Heterogeneity: ChiP = 2.01, df = 6 (P = 0.92); P = 0% Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9 | restion overall ellect. | 2-0.15 | ,r = 0.0 | .0) | | | | | Favours [TELD] Favours [IELD] | | | |
| Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl Choi 2013 1 30 2 30 7.5% 0.50 [0.05, 5.22] Huang 2021 2 37 3 40 10.9% 0.72 [0.13, 4.08] Mlaka 2020 5 103 4 83 16.7% 1.01 [0.28, 3.63] Nie 2016 0 30 1 30 5.7% 0.33 [0.01, 7.87] Rajamani 2021 6 86 8 80.2% 0.75 [0.27, 2.07] Sebben 2021 1 24 0 31 1.7% 3.84 [0.16, 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% Cl) 397 405 100.0% 0.92 [0.54, 1.57] 100 Total events 23 26 100.0% 0.92 [0.54, 1.57] 100 Total (95% Cl) 31 1.57 100.0% 0.92 [0.01, 6.88] 1001 0.1 1 | В | TELI | 0 | IELD |) | | Risk Ratio | | Risk Ratio | | | |
| Choi 2013 1 30 2 30 7.5% 0.50 [0.05, 5.22] Huang 2021 2 37 3 40 10.9% 0.72 [0.13, 4.08] Mika 2020 5 103 4 83 16.7% 1.01 [0.28, 3.63] Nie 2016 0 30 1 30 5.7% 0.33 [0.01, 7.87] Rajamani 2021 6 86 8 86 30.2% 0.75 [0.27, 2.07] Sebben 2021 1 24 0 31 1.7% 3.84 [0.16, 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% CI) 397 405 100.0% 0.92 [0.54, 1.57] Total events 23 26 Heterogeneity: Chi ² = 2.01, df = 6 (P = 0.92); P = 0% Test for overall effect Z = 0.29 (P = 0.77) C Test for overall effect Z = 0.29 (P = 0.77) Risk Ratio Mika 2020 1 103 16.4% 0.96 [0.10, 9.68] Liu 2017 0 31 1.27 19.5% 0.29 [0.01, 6.88] Mo2019 0 39 | Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% Cl | | M-H, Fixed, 95% Cl | | | |
| Huang 2021 2 37 3 40 10.9% 0.72 [0.13, 4.08] Miaka 2020 5 103 4 83 16.7% 1.01 [0.28, 3.63] Nie 2016 0 30 1 30 5.7% 0.33 [0.01, 7.87] Rajamani 2021 6 86 86 80 30.2% 0.75 [0.27, 2.07] Sebben 2021 1 24 0 31 1.7% 3.84 [0.16, 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% CI) 397 405 100.0% 0.92 [0.54, 1.57] Total events 23 26 Heterogeneity: Chi ^P = 2.01, df = 6 (P = 0.92); P = 0% Total Weight M-H, Fixed, 95% CI Chen 2019 2 27 1 13 16.4% 0.98 [0.10, 9.68] Liu 2017 0 31 1 27 19.5% 0.29 [0.01, 16.88] Miaka 2020 1 103 83 13.5% 0.35 [0.01, 8.34] 0.35 [0.01, 8.34] Maka 2021 0 24 2 26.7% </td <td>Choi 2013</td> <td>1</td> <td>30</td> <td>2</td> <td>30</td> <td>7.5%</td> <td>0.50 (0.05, 5.22)</td> <td></td> <td>· · · · ·</td> <td></td> | Choi 2013 | 1 | 30 | 2 | 30 | 7.5% | 0.50 (0.05, 5.22) | | · · · · · | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Huang 2021 | 2 | 37 | 3 | 40 | 10.9% | 0.72 [0.13, 4.08] | | | | | |
| Nie 2016 0 30 1 30 5.7% 0.33 [0.01, 7.87] Rajamani 2021 6 86 8 80 30.2% 0.75 [0.27, 2.07] Sebben 2021 1 24 0 31 1.7% 3.84 [0.16, 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% Cl) 397 405 100.0% 0.92 [0.54, 1.57] Total events 23 26 Heterogeneity: Chi ² = 2.01, df = 6 (P = 0.92); P = 0% Test for overall effect: Z = 0.29 (P = 0.77) Risk Ratio Risk Ratio Study or Subgroup Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] M-H, Fixed, 95% Cl Liu 2017 0 31 27 19.5% 0.29 [0.01, 6.88] M-H, Fixed, 95% Cl Mlaka 2020 1 103 1 83 13.5% 0.81 [0.05, 12.69] Mo 201 [0.01, 9.68] Mo 2019 0 39 1 41 17.8% 0.26 [0.01, 5.10] <td>Mlaka 2020</td> <td>5</td> <td>103</td> <td>4</td> <td>83</td> <td>16.7%</td> <td>1.01 [0.28, 3.63]</td> <td></td> <td></td> <td></td> | Mlaka 2020 | 5 | 103 | 4 | 83 | 16.7% | 1.01 [0.28, 3.63] | | | | | |
| Rajamani 2021 6 86 8 80 30.2% 0.75 [0.27 , 2.07] Sebben 2021 1 24 0 31 1.7% 3.84 [0.16 , 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47 , 3.08] Total (95% CI) 397 405 100.0% 0.92 [0.54 , 1.57] Total events 23 26 Heterogeneity: Chi ² = 2.01, df = 6 (P = 0.92); P = 0% Risk Ratio Risk Ratio Study or Subgroup Tetal Ford Events Total Weight M-H, Fixed, 95% CI Chen 2019 2 27 1 13 16.4% 0.96 [0.10 , 9.68] M-H, Fixed, 95% CI Liu 2017 0 31 1 27 19.5% 0.29 [0.01 , 6.88] Mlaka 2020 1 103 1 83 13.5% 0.81 [0.05 , 12.69] Mo 2019 0 39 1 41 17.8% 0.36 [0.01 , 5.10] Maka 2020 1 103 24 23 26.7% 0.26 [0.01 , 5.10] Total (95% CI) <th< td=""><td>Nie 2016</td><td>0</td><td>30</td><td>1</td><td>30</td><td>5.7%</td><td>0.33 [0.01, 7.87]</td><td></td><td></td><td></td></th<> | Nie 2016 | 0 | 30 | 1 | 30 | 5.7% | 0.33 [0.01, 7.87] | | | | | |
| Sebben 2021 1 24 0 31 1.7% 3.84 [0.16, 90.29] Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% Cl) 397 405 100.0% 0.92 [0.54, 1.57] Total events 23 26 Heterogeneity: Chi ² = 2.01, df = 6 (P = 0.92); I ² = 0% Events Total Kesk Ratio Test for overall effect Z = 0.29 (P = 0.77) Events Total Weight M-H, Fixed, 95% Cl C TELD ELD Risk Ratio Risk Ratio Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] Liu 2017 0 31 1 27 19.5% 0.29 [0.01, 6.88] Mlaka 2020 1 103 1 83 13.5% 0.81 [0.05, 12.69] Mo 2019 0 39 1 41 7.8% 0.26 [0.01, 5.10] Maka 2020 1 103 281 100.0% 0.64 [0.22, 1.88] Total (95% Cl) 310 281 100.0% 0.64 [0.22, 1.88] Total events | Raiamani 2021 | 6 | 86 | 8 | 86 | 30.2% | 0.75 [0.27, 2.07] | | | | | |
| Wei 2021 8 87 8 105 27.4% 1.21 [0.47, 3.08] Total (95% Cl) 397 405 100.0% 0.92 [0.54, 1.57] Total events 23 26 Heterogeneity: Chi ² = 2.01, df = 6 (P = 0.92); P = 0% 0.01 0.1 10 100 Test for overall effect: Z = 0.29 (P = 0.77) IELD IELD Risk Ratio Risk Ratio C Test for overall effect: Z = 0.29 (P = 0.77) IIII 13 16.4% 0.96 [0.10, 9.68] M.H., Fixed, 95% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] Liu 2017 0 31 1 27 19.5% 0.29 [0.01, 6.88] Miaka 2020 1 103 1 83 13.5% 0.81 [0.05, 12.69] Mo 2019 0 39 1 41 17.8% 0.36 [0.01, 8.34] Rajamani 2021 1 86 86 6.1% 3.00 [0.12, 72.63] 96 Sebben 2021 0 24 2 100.0% 0.64 [0.22, 1.88] 0.01 0.01 0.01 0.01 0.01 < | Sebben 2021 | 1 | 24 | n | 31 | 1.7% | 3 84 0 16 90 291 | | | | | |
| Total (95% Cl) 397 405 100.0% 0.92 [0.54, 1.57] Total events 23 26 Heterogeneity: $Chi^{F} = 2.01$, $df = 6$ (P = 0.92); P = 0% 0.01 0.1 10 Test for overall effect: $Z = 0.29$ (P = 0.77) ELD ELD Risk Ratio C Test for overall effect: $Z = 0.29$ (P = 0.77) Fevents Total Weight M-H, Fixed, 95% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] M-H, Fixed, 95% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 5, 12.69] M-H, Fixed, 95% Cl Mlaka 2020 1 103 1 83 13.5% 0.81 [0.05, 12.69] Mo 2019 0 39 1 41 17.8% 0.35 [0.01, 8.34] Maka 2020 1 103 1 26.7% 0.26 [0.01, 5.10] 0.4 Mo 2019 0 39 1 41 6.1% 3.00 [0.12, 72.63] 0.4 Sebben 2021 0 24 2 31 26.7% 0.26 [0.01, 5.10] 0.1 0.1 0.1 </td <td>Wei 2021</td> <td>8</td> <td>87</td> <td>8</td> <td>105</td> <td>27.4%</td> <td>1.21 [0.47. 3.08]</td> <td></td> <td></td> <td></td> | Wei 2021 | 8 | 87 | 8 | 105 | 27.4% | 1.21 [0.47. 3.08] | | | | | |
| Total (95% Cl) 397 405 100.0% 0.92 [0.54, 1.57] Total events 23 26 Heterogeneity: Chi ² = 2.01, df = 6 (P = 0.92); l ² = 0% 0.01 0.1 10 Test for overall effect: Z = 0.29 (P = 0.77) IELD Risk Ratio Risk Ratio Study or Subgroup IELD IELD Risk Ratio N-H, Fixed, 95% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] Liu 2017 0 31 1 27 19.5% 0.29 [0.01, 6.88] Miaka 2020 1 103 1 83 13.5% 0.81 [0.05, 12.69] Mo 2019 0 39 1 41 17.8% 0.35 [0.01, 8.34] Rajamani 2021 1 86 0 86 6.1% 3.00 [0.12, 72.63] Sebben 2021 0 24 2 31 26.7% 0.26 [0.01, 5.10] Total (95% Cl) 310 281 100.0% 0.64 [0.22, 1.88] 0.01 0.1 0.1 0.1 0.1 0.1 0.01 0.01 0.01 0.01 0.01 | | | | | | | | | | | | |
| Total events 23 26 Heterogeneity: $Chi^2 = 2.01$, $df = 6$ (P = 0.92); $l^2 = 0\%$ Test for overall effect: $Z = 0.29$ (P = 0.77) C Tell Favours [TELD] IELD Risk Ratio Study or Subgroup Tell Fvents Total Weight M-H, Fixed, 95% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] Liu 2017 0 31 1 27 19.5% 0.29 [0.01, 6.88] Maka 2020 1 103 1 83 13.5% 0.81 [0.05, 12.69] Mo 2019 0 39 1 41 17.8% 0.35 [0.01, 8.34] Rajamani 2021 310 281 100.0% 0.64 [0.22, 1.88] 0.01 0.01 0.1 100 Total (95% Cl) 310 281 100.0% 0.64 [0.22, 1.88] 0.01 0.01 0.1 100 Total events 4 6 6 100.0% 0.64 [0.22, 1.88] 0.01 0.01 0.1 100 100 Total events 4 6 6 0.01 0.1 0.01 0 | Total (95% CI) | | 397 | | 405 | 100.0% | 0.92 [0.54, 1.57] | | • | | | |
| Heterogeneity: $Chi^2 = 2.01$, $df = 6$ ($P = 0.92$); $ P = 0.\%$ Test for overall effect: $Z = 0.29$ ($P = 0.77$) C TELD Risk Ratio Study or Subgroup Test for overall effect: $Z = 0.29$ ($P = 0.77$) C Test for overall effect: $Z = 0.29$ ($P = 0.77$) C Test for overall effect: $Z = 0.29$ ($P = 0.77$) Colspan="4">Test for overall effect: $Z = 0.29$ ($P = 0.77$) Colspan="4">Test for overall effect: $Z = 0.29$ ($P = 0.77$) Colspan="4">Test for overall effect: $Z = 0.92$ ($P = 0.77$) Test for overall effect: $Z = 0.92$ ($P = 0.77$) Test for overall effect: $Z = 0.92$ ($P = 0.77$) Test for overall effect: $Z = 0.92$ ($P = 0.77$) Test for overall effect: $Z = 0.82$ ($P = 0.41$) Test for overall effect: $Z = 0.82$ ($P = 0.41$) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) | Total events | 23 | | 26 | | | | | | | | |
| Test for overall effect: $Z = 0.29$ (P = 0.77) Favours [TELD] Favours [TELD] Favours [TELD] Favours [TELD] Favours [TELD] Favours [TELD] Favours [TELD] Favours [TELD] Study or Subgroup Events Total Weight M-H, Fixed, 95% CI Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] Liu 2017 0 31 13.5% 0.29 [0.01, 6.88] Maka 2020 1 103 1 1 7.8% 0.35 [0.01, 8.81] Maka 2020 1 1 1 Risk Ratio Mikka 2021 1 8 6 Maka 2021 0 24 2 31 26.7% 0.26 [0.01, 5.10] 0.01 0 | Heterogeneity: Chi ² = | 2.01, df= | 6 (P = | 0.92); l² = | = 0% | | | 0.01 | 01 1 10 | 100 | | |
| C TEL D IEL D Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] M-H, Fixed, 95% CI Liu 2017 0 31 1 27 19.5% 0.29 [0.01, 6.88] Image: Comparison of the state of the st | Test for overall effect: | Z=0.29 (| (P = 0.7 | 7) | | | | | Favours [TELD] Favours [IELD] | | | |
| C Tell Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] Image: constraint of the second secon | 0 | TEL | | | | | Diale Datia | | Diek Datie | | | |
| Study of Subgroup Events Total Events Total Vergin M-1, Fixed, 55% Cl M-1, Fixed, 55% Cl Chen 2019 2 27 1 13 16.4% 0.96 [0.10, 9.68] Image: state of the state of | C Study or Subgroup | Evente | Total | Evonte | Total | Moight | M H Eivad 05% CL | | M H Eixed 05% Cl | | | |
| Chefr 2019 2 27 1 13 10.4% 0.361(0.10, 5.08) Liu 2017 0 31 1 27 19.5% 0.29 [0.01, 6.88] Mlaka 2020 1 103 1 83 13.5% 0.81 [0.05, 12.69] Mo 2019 0 39 1 41 17.8% 0.35 [0.01, 8.34] Rajamani 2021 1 86 0 86 6.1% 3.00 [0.12, 72.63] Sebben 2021 0 24 2 31 26.7% 0.26 [0.01, 5.10] Total (95% CI) 310 281 100.0% 0.64 [0.22, 1.88] Total events 4 6 Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); ² = 0% 0.01 0.1 1 10 100 Test for overall effect Z = 0.82 (P = 0.41) 50% 50% 50% 50% 50% 50% | Chap 2010 | LVCIILO | 27 | LVCIILO | 10 | 16 A0 | 0.06 (0.10.0.60) | | M-1, 11/eu, 55% Cl | | | |
| Lid 2017 0 31 1 27 13.5% $0.23[0.01, 0.83]$ Mlaka 2020 1 103 1 83 13.5% $0.81[0.05, 12.69]$ Mo 2019 0 39 1 41 17.8% $0.35[0.01, 8.34]$ Rajamani 2021 1 86 0 86 6.1% $3.00[0.12, 72.63]$ Sebben 2021 0 24 2 31 26.7% $0.26[0.01, 5.10]$ Total (95% CI) 310 281 100.0% $0.64[0.22, 1.88]$ Total events 4 6 Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); ² = 0% 0.01 0.1 1 10 100 | Liu 2017 | 2 | 27 | 1 | 27 | 10.4% | | 8 | | | | |
| Miraka 2020 1 103 13.30 0.01 [0.03, 12.03] Mo 2019 0 39 1 41 17.8% 0.35 [0.01, 8.34] Rajamani 2021 1 86 0 86 6.1% 3.00 [0.12, 72.63] Sebben 2021 0 24 2 31 26.7% 0.26 [0.01, 5.10] Total (95% Cl) 310 281 100.0% 0.64 [0.22, 1.88] Total events 4 6 Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); l ² = 0% 0.01 0.1 10 100 Test for overall effect Z = 0.82 (P = 0.41) 50% 50% 50% 50% 50% 50% | Miaka 2020 | 1 | 102 | 1 | 21 | 13.5% | | | | | | |
| Image: Non-Sector of Sector of Sect | Maka 2020 Mo 2010 | 0 | 20 | 1 | 41 | 17.0% | 0.01 [0.00, 12.03] | 8- <u>-</u> | | | | |
| Total (95% Cl) 310 281 100.0% 0.64 [0.22, 1.88] Total events 4 6 Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); ² = 0% 0.01 0.1 1 10 100 Total for overall effect Z = 0.82 (P = 0.41) 0.01 0.1 1 10 100 | Rajamani 2021 | 1 | 20 | , 0 | 06 | 6 1 96 | 2 00 00 12 72 621 | | | | | |
| Total (95% Cl) 310 281 100.0% 0.64 [0.22, 1.88] Total events 4 6 Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); l ² = 0% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.82 (P = 0.41) 0.01 0.1 1 10 100 | Rajamani 2021 Sobbon 2021 | 0 | 24 | 2 | 21 | 26.7% | 0.2610.01 6.101 | | | | | |
| Total (95% CI) 310 281 100.0% 0.64 [0.22, 1.88] Total events 4 6 Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); l ² = 0% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.82 (P = 0.41) 0.01 0.1 1 10 100 | 3666611 2021 | U | 24 | 2 | 51 | 20.7 % | 0.20 [0.01, 5.10] | | - | | | |
| Total events 4 6 Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); l ² = 0% 1 10 100 Test for overall effect: Z = 0.82 (P = 0.41) 0.01 0.1 1 100 | Total (95% CI) | | 310 | | 281 | 100.0 % | 0.64 [0.22, 1.88] | | | | | |
| Heterogeneity: Chi ² = 1.79, df = 5 (P = 0.88); l ² = 0% Test for overall effect: Z = 0.82 (P = 0.41) Test for overall effect: Z = 0.82 (P = 0.41) | Total events | 4 | | 6 | | | | | | | | |
| Favours ITELDI Favours ITELDI | Heterogeneity: Chi² = Test for overall effect: | 1.79, df = Z = 0.82 (| 5 (P = (P = 0.4 | 0.88); I² = 1) | = 0% | | | 0.01 | 0.1 1 10 Favours (TELD) Favours (IELD) | 100 | | |

Figure 4. Forest plot showing effect sizes and 95% CI in the complications, comparing overall complications (A), rate of recurrent disc herniation (B) and dural tear (C) between TELD and IELD. TELD, transforaminal endoscopic lumbar discectomy; IELD, interlaminar endoscopic lumbar discectomy; SD, standard deviation; CI, confidence interval; df, degrees of freedom.

of anesthesia. Usually, TELD was performed under local anesthesia, while IELD was operated under general anesthesia which possibly led to a slight delay in postoperative ambulation due to the effects of anesthetic agent. Nevertheless, from the current study, this delay in ambulation was very subtle and unlikely to affect patient's condition and satisfaction postoperatively. In addition, the length of hospital stay was not different between both approaches. For the comparison of estimated blood loss, despite of significant difference in amount of blood loss between both techniques from our analysis, no studies had mentioned the methods of measuring blood loss under endoscope. Thus, we believed that this difference would not have any clinical significance.

The improvement of functional outcomes was analyzed as the primary outcome of this meta-analysis. Postoperative results were favorable following both techniques with significant improvement of functional scores, demonstrating that both approaches were effective in alleviating patients' symptoms and recovering their function. To the best of our knowledge, our study is the first meta-analysis to detect the improvement of clinical outcomes, by analyzing the difference between pre- and postoperative function scores. ODI improvement in the early postoperative period was slightly better following TELD than IELD but did not achieve MCID, and no difference was detected at the last follow-up. Interestingly, the VASB reduction was more effective with IELD at both early postoperative period and the last follow-up with statistical significance. Nevertheless, the mean difference in back pain reduction was very subtle (less than one point) and failed to achieve the MCID. These findings were in accordance with previous meta-analyses that identified similar effects in pain reduction and function recovery between 2 approaches.^{29,32} In addition, our study found that the VASL reduction was also not different between both groups, but with significant heterogeneity. The source of heterogeneity was from Huang et al.¹⁵ who reported clinical outcomes following endoscopic discectomy focusing only highly down-migrated LDH. Complete removal of highly down-migrated disc material was likely more difficult to achieve via TELD approach, possibly leading to a residual remnant of disc fragment following the surgery and unrelieved leg pain.¹⁵ Patient satisfaction assessed by MacNab criteria was also not different between both approaches. Moreover, subgroup analysis for TELD and IELD at L5-S1 level revealed similar results to operation at other levels. Our demonstrated findings were correlated with previous studies, indicating that both techniques could successfully remove the herniated disc material, and adequately decompress the nerve root, while preserving spinal stability in comparable effectiveness. However, performing TELD in L5-S1 level or highly migrated disc herniation was feasible but could be a challenge, requiring surgeon's experience, longer operative time and more fluoroscopic use.

For evaluation of procedure safety, we performed a comparative analysis of the complications. Our study found no evident differences in overall complications between TELD and IELD. Regardless of the surgical approaches, the overall complication rate was approximately 11% which was correlated with previous meta-analysis by Yin et al.³³ regarding complications following TELD and IELD. Moreover, rates of recurrent disc herniation and dural tear did not significantly differ between both groups. The rates of dural tear following both techniques were relatively low (less than 3%), in accordance with a survey study by Lewandrowski et al.,³⁴ but they reported a higher risk of dural tear in IELD than TELD due to the use of power tools or sharp instruments during ligamentum flavum resection and the fragile posterior dural sac exposure. However, we believe that surgeons' learning curve significantly affected the complication rates.

According to the surgical anatomy combined with our comparative results between the 2 approaches, our recommendations on approach selection for endoscopic discectomy were as follows: Basically, the zone of disc herniation should be the first factor to consider. Foraminal or extraforaminal disc herniation should be treated with transforaminal approach. Herniated disc at L5-S1 level is more easily accessed with interlaminar approach due to the hindrance of iliac crest height. Usually, high-grade migrated disc removal is more comfortably performed with interlaminar approach due to more flexible working window than the transforaminal trajectory. However, due to the possibility to operate under local anesthesia, TELD has advantages in patients with multiple comorbidities with high risk of general anesthesia. Apart from these considerations, the results following TELD and IELD were comparable and decision-making on approach selections should depend on the surgeon's preference, experiences, and individual, case-by-case consideration.

The strengths of this meta-analysis were as follows: First, as mentioned earlier, this study is the first metaanalysis that focuses on the comparison of the degree of improvement of clinical outcomes which was more valuable, in contrast to previous meta-analyses that mostly compared the functional scores directly. Moreover, the functional outcome improvement was analyzed in both early postoperative and last follow-up periods. Second, we conducted a subgroup analysis for the highly heterogeneous outcome, such as functional outcomes in L5-S1 LDH surgery. Third, the current study included updated high-quality evidence with a large number of total participants from different countries, as most of the previous literature included articles in Chinese which may affect generalizability.

There were some limitations to our study. First, most of the included studies were retrospective and nonrandomized prospective studies that were subjected to selection bias and incomplete data. Second, some of the outcome variables had significant heterogeneity that may affect the reliability of the comparative analysis. Third, several confounding factors may contribute to postoperative outcomes following TELD and IELD such as different surgeon's skills, learning curve, and modifications of endoscopic techniques from each center or subjects from different countries may affect the outcome measures.

Despite these limitations, our meta-analysis reported comparative results of TELD and IELD, focusing on functional outcomes improvement and could guide spine surgeons to consider evidence from this study to select the appropriate approach of endoscopic lumbar discectomy for their patients and also informed consent for risk and benefits of each procedure.

Conclusion

This meta-analysis was the first to compare TELD and IELD for treating LDH focusing on the improvement of clinical outcomes. We found comparable functional outcomes in terms of ODI and VAS improvement, patient satisfaction, hospital stays, and similar complication rates between both techniques. IELD required a slightly longer period of postoperative bed rest. TELD required more radiation exposure than IELD and also had a longer operative time at L5-S1 level. Our study could be helpful for surgeons to consider which approach is suitable for selected patients and also informed consent of the advantages of each approach before performing endoscopic lumbar discectomy.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.-S.K. is a consultant of Richard Wolf, GmbH, and Elliquence, LLC.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Data Availability Statement

Data will be available by contacting J.-S.K. the corresponding author, at the above address.

ORCID iDs

Khanathip Jitpakdee (b) https://orcid.org/0000-0003-2533-6398 Jin-Sung Kim (b) https://orcid.org/0000-0001-5086-0875

References

- Postacchini F, Cinotti G, Gumina S. Microsurgical excision of lateral lumbar disc herniation through an interlaminar approach. *J Bone Joint Surg Br.* 1998;80(2):201-207.
- 2. Stromqvist F, Stromqvist B, Jonsson B, Karlsson MK. Surgical treatment of lumbar disc herniation in different ages-evaluation of 11, 237 patients. *Spine J.* 2017;17(11):1577-1585.
- Li WS, Yan Q, Cong L. Comparison of endoscopic discectomy versus non-endoscopic discectomy for symptomatic lumbar disc herniation: A systematic review and meta-analysis. *Global Spine J.* 2021;12:1012-1026.
- Li M, Yang H, Yang Q. Full-endoscopic technique discectomy versus microendoscopic discectomy for the surgical treatment of lumbar disc herniation. *Pain Physician*. 2015;18(4):359-363.
- Won YI, Yuh WT, Kwon SW, et al. Interlaminar endoscopic lumbar discectomy: A narrative review. *Int J Spine Surg.* 2021; 15(suppl 3):S47-S53.
- Wu PH, Kim HS, Jang IT. A narrative review of development of full-endoscopic lumbar spine surgery. *Neurospine*. 2020; 17(Suppl 1):S20-S33.
- Kambin P, Sampson S. Posterolateral percutaneous suctionexcision of herniated lumbar intervertebral discs. Report of interim results. *Clin Orthop Relat Res.* 1986;207:37-43.
- Ruetten S, Komp M, Merk H, Godolias G. Full-endoscopic interlaminar and transforaminal lumbar discectomy versus conventional microsurgical technique: a prospective, randomized, controlled study. *Spine (Phila Pa 1976)*. 2008;33(9): 931-939.

- Liu Y, Kim J-S, Chen C-M, et al. A review of full-endoscopic interlaminar discectomy for lumbar disc disease: A historical and technical overview. *J Minim Invasive Spine Surg Tech*. 2021;6(Suppl 1):S109-S116.
- Choi G, Lee SH, Raiturker PP, Lee S, Chae YS. Percutaneous endoscopic interlaminar discectomy for intracanalicular disc herniations at L5-S1 using a rigid working channel endoscope. *Neurosurgery*. 2006;58(1 Suppl):ONS59-ONS68.
- 11. Bamrungthin N. Comparation of percutaneous endoscopic lumbar discectomy between transforaminal approach and interlaminar approach on lumbar disc herniation of L4-L5: An observational study. *J Med Assoc Thailand*. 2020;103(12):1277-1283.
- Cheng YP, Cheng XK, Wu H. A comparative study of percutaneous endoscopic interlaminar discectomy and transforaminal discectomy for L5-S1 calcified lumbar disc herniation. *BMC Musculoskelet Disord*. 2022;23(1):244.
- Choi KC, Shim HK, Kim JS, et al. Cost-effectiveness of microdiscectomy versus endoscopic discectomy for lumbar disc herniation. *Spine J.* 2019;19(7):1162-1169.
- Gao A, Yang H, Zhu L, et al. Comparison of interlaminar and transforaminal approaches for treatment of L(5) /S(1) disc herniation by percutaneous endoscopic discectomy. *Orthop Surg.* 2021;13(1):63-70.
- Huang K, Chen G, Lu S, et al. Early clinical outcomes of percutaneous endoscopic lumbar discectomy for L4-5 highly downmigrated disc herniation: Interlaminar approach versus transforaminal approach. *World Neurosurg.* 2021;146:e413-e418.
- Jiang X, Zhou X, Xu N. Clinical effects of transforaminal and interlaminar percutaneous endoscopic discectomy for lumbar disc herniation: A retrospective study. *Medicine (Baltimore)*. 2018;97(48):e13417.
- Liu C, Chu L, Yong HC, Chen L, Deng ZL. Percutaneous endoscopic lumbar discectomy for highly migrated lumbar disc herniation. *Pain Phys.* 2017;20(1):E75-E84.
- Mo X, Shen J, Jiang W, et al. Percutaneous endoscopic lumbar diskectomy for axillar herniation at L5-S1 via the transforaminal approach versus the interlaminar approach: A prospective clinical trial. *World Neurosurg.* 2019;125:e508-e514.
- Nie H, Zeng J, Song Y, et al. Percutaneous endoscopic lumbar discectomy for L5-S1 disc herniation via an interlaminar approach versus a transforaminal approach: A prospective randomized controlled study with 2-year follow up. *Spine (Phila Pa* 1976). 2016;41(Suppl 19):B30-B37.
- Rajamani PA, Goparaju P, Kulkarni AG, et al. A 2-year outcomes and complications of various techniques of lumbar discectomy: A multicentric retrospective study. *World Neurosurg.* 2021;156:e319-e328.
- Wei H, Shunli K, Zehua J, Tengfei Z, Yidong L, Rusen Z. Comparative study of three minimally invasive surgical approaches for the treatment of L5/S1 lumbar intervertebral disc herniation. *Turk Neurosurg*. 2021;31(3):324-332.
- 22. Wu C, Lee CY, Chen SC, Hsu SK, Wu MH. Functional outcomes of full-endoscopic spine surgery for high-grade migrated lumbar disc herniation: A prospective registry-based cohort

study with more than 5 years of follow-up. *BMC Musculoskelet Disord*. 2021;22(1):58.

- Yan Y, Zhu M, Cao X, et al. Different approaches to percutaneous endoscopic lumbar discectomy for L5/S1 lumbar disc herniation: A retrospective study. *Br J Neurosurg*. 2020; 1-7.
- Yin G, Wang C, Liu SQ. Comparative analysis of the therapeutic efficiency and radiographic measurement between the transforaminal approach and interlaminar approach in percutaneous endoscopic discectomy. *Turk Neurosurg*. 2021;31(6): 857-865.
- Choi KC, Kim JS, Ryu KS, Kang BU, Ahn Y, Lee SH. Percutaneous endoscopic lumbar discectomy for L5-S1 disc herniation: Transforaminal versus interlaminar approach. *Pain Phys.* 2013;16(6):547-556.
- Chen Y, Wang JX, Sun B, et al. Percutaneous endoscopic lumbar discectomy in treating calcified lumbar intervertebral disc herniation. *World Neurosurg*. 2019;122:e1449-e1456.
- 27. Mlaka J, Rapcan R, Burianek M, et al. Endoscopic discectomy as an effective treatment of a herniated intervertebral disc. *Bratisl Lek Listy.* 2020;121(3):199-205.
- Sebben AL, Kulcheski ÅL, Graells XSI, Benato ML, Santoro PGD. Comparison of two endoscopic spine surgical techniques. *Rev Assoc Med Bras 1992*. 2021;67(2):243-247.

- He DW, Xu YJ, Chen WC, et al. Meta-analysis of the operative treatment of lumbar disc herniation via transforaminal percutaneous endoscopic discectomy versus interlaminar percutaneous endoscopic discectomy in randomized trials. *Medicine (Baltimore)*. 2021;100(5):e23193.
- Ahn Y, Kim CH, Lee JH, Lee SH, Kim JS. Radiation exposure to the surgeon during percutaneous endoscopic lumbar discectomy: A prospective study. *Spine (Phila Pa 1976)*. 2013;38(7):617-625.
- Qin H, Huang S, Xu L, et al. Radiation exposure and operation time in percutaneous endoscopic lumbar discectomy using fluoroscopy-based navigation system. *World Neurosurg*. 2019; 127:e39-e48.
- Huang Y, Yin J, Sun Z, et al. Percutaneous endoscopic lumbar discectomy for LDH via a transforaminal approach versus an interlaminar approach: A meta-analysis. *Orthopade*. 2020;49(4):338-349.
- Yin J, Jiang Y, Nong L. Transforaminal approach versus interlaminar approach: A meta-analysis of operative complication of percutaneous endoscopic lumbar discectomy. *Medicine* (*Baltimore*). 2020;99(25):e20709.
- Lewandrowski KU, Hellinger S, De Carvalho PST, et al. Dural tears during lumbar spinal endoscopy: Surgeon skill, training, incidence, risk factors, and management. *Int J Spine Surg*. 2021; 15(2):280-294.